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ABSTRACT
Ajumobi, Taiwo. M.S., Butler University, December 2014. Beta- blockers act
through clathrin-dependent internalization and EGFR transactivation to promote
ERK phosphorylation. Major Professor: Medhane Cumbay.
For cardiovascular diseases such as high blood pressure, angina pectoris, and left
ventricle hypertrophy; long-term activation of beta-adrenergic receptors is strongly linked
to the progression of these diseases. A class of antagonistic drugs that target beta-
adrenergic receptors are collectively called beta-blockers. These drugs are commonly
used to reduce the inotropic and chronotropic effects of beta-adrenergic receptor
activation. This past decade has revealed that beta-blockers and other ligands are capable
of functional selectivity at receptors. Functional selectivity describes the ability of ligands
acting at 0 protein-coupled receptors (OPCRs) to preferentially activate or inhibit
different signal transduction pathways. The studies on beta-adrenergic 2 receptors that
explored functional selectivity showed that beta-blockers can be functionally selective by
inhibiting the cAMP pathway while simultaneously activating ERK. The 0 protein
coupled to beta-adrenergic receptors are the primary regulators of the cAMP, however
there are a variety of pathways that can regulate ERK activity and few studies have tried
to determine which pathway(s) the beta-blockers are targeting to cause this ERK
activation. This is especially important for beta-adrenergic 2 receptors because they can
activate ERK through multiple pathways (0 protein switching from G, to Oi/oprotein,
beta-arrestin assisted or EOFR transactivation). ERK activation is linked to reversing cell
damage caused by apoptosis signaling that results from G, activation by beta-adrenergic
receptors. Understanding the specific pathways these beta-blockers can target for ERK
activation would lead to better understanding of their therapeutic benefits. In this study
we plan to elucidate the pathways several beta-blockers are targeting to activate ERK. In
particular, we will investigate the role of clathrin-mediated receptor internalization and
ix
EGFR transactivation in beta-blocker-dependent ERK phosphorylation. In HEK 293 cells
transfected with beta-adrenergic 2 receptors, we measured the changes in cAMP and
ERK phosphorylation in response to the following beta-blockers labetalol, alprenolol,
bucindolol, carvedilol, carazolol, leI 118,551 and propanolol. All of the beta-blockers
studied inhibited isoproterenol-stimulated cAMP accumulation but stimulated the
phosphorylation of ERK to varying degrees. Beta-blocker-mediated ERK
phosphorylation was shown to be dependent on clathrin-dependent internalization and
EGFR transactivation.
1CHAPTER 1: INTRODUCTION
1.1 Overview of G protein Coupled Receptors
In the human genome there are over 800 genes that make up estimated thousands of
receptors including their splice variants which are collectively classified as G protein
coupled Receptors (GPCRs) (Luttrell 2008). These receptors' responses to diverse stimuli
(such as different tastes, smells, and the presence of neurotransmitters in the extracellular
space) make them ideal targets for drug design. Currently over 50% of all drugs in the
market target these receptors (Flower 1999, Luttrell 2008). A common feature with
GPCRs is their structure. GPCRs have seven hydrophobic alpha helices that are linked by
three extracellular loops and three intracellular loops as shown in Figure 1 (Boekart 2001,
Luttrell 2008, Paavolva 2012).
2B
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Figure 1: Schematic of the seven transmembrane structure of a G protein coupled receptor. A) Shows the 2D structure
of a GPCR with the seven transmembranes, three intracellular (en do) loops and three exocellular loops. B) Shows a 3D
setup of how the receptors are oriented in plasma membrane. SOURCE FOR IMAGE: Flower, Darren R. "Modelling G
protein-coupled receptors for drug design."Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes 1422.3
(1999): 207-234.
As their name implies, GPCRs are coupled to a heterotrimeric guanine nucleotide binding
proteins also known as a G proteins. When activated, the G protein uncouples from the
receptor and initiates activation of different signaling pathways.
GCPRs are also categorized based on 1) how they interact with a ligand, and 2) their
affinity for beta-arrestins. The most common method of GPCR grouping is by how a
receptor interacts with a ligand. Group A (rhodopsin-like) GPCR receptors interact with
their respective ligands in binding pockets within their transmembrane domains (Luttrell
2002, Boekart 2002, Pierce 2002, Foord 2005). This group has the largest number of
3receptors and includes dopamine receptors, rhodopsin receptors, adrenergic receptors,
and serotonin receptors. The physiological ligands these receptors interact with include
biogenic amines such as dopamine and epinephrine or other stimuli such as light and
odorants (Prinster 2005, Luttrell 2008). In contrast, Group B receptors bind with large
peptide hormones such as secretin, calcitonin, and glucagon. In addition to their
transmembrane regions, this GPCR group also use their N-terminal and extracellular
loops to coordinate ligand binding (Hamar 2001). These receptors are found in a variety
of cells but are mainly expressed in the brain and the liver (Boekart 2001, Harmar 2001
Foord 2005). Group C GPCRs include GABA receptors, glutamate receptors, and taste
receptors. These receptors are primarily expressed in the brain and are known for having
a large extracellular domain separate from the seven transmembranes which is important
for its ligand binding ability (Chun 2012). Another characteristic of Group C GPCR
receptors is that they dimerize when bound by a ligand (Prinster 2005, Gurevich 2008,
Chun 2012). There are other receptors that aren't in Groups A, B, or C but instead fall
into Groups D-F. Examples of these receptors are Frizzled receptors, smothered receptors,
and orphan receptors; however there is little concrete evidence on their physiological
roles.
1.1.2 G protein Coupled Receptors Activation
4GPCRs within the same grouping can differ from each other by the type of G protein
they couple to. For example, dopamine Dl receptors are coupled to G, proteins; in
contrast, the dopamine D2 receptors are coupled to Gilo proteins (Beaulieu 2011).
Regardless of the G protein coupled to the receptor, when an agonist binds to the receptor,
the receptor undergoes a conformational change that results in the G protein dissociating
into its alpha and beta-gamma subunits as Figure 2 shows (Rosenbaum 2009, Paavola
2012). Upon separation, each subunit activates their respective pathways. The cause of
the G protein separation is the conformational change the alpha subunit undergoes when
the GPD bound to it is replaced by a GTP found in the intracellular environment
(Rosenbaum 2009).
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Figure 2: Activation ofG protein Coupled Receptor (GPCR). SOURCE FOR IMAGE: Tuteja, Narendra. "Signaling
through G protein coupled receptors." Plant Signal Behav 4.10 (2009): 942-947.
5In mammals there are a total of eight different alpha subunit isoforms (as, ai 1-3,aq, a12-I3,
a olfand transducin). Depending on alpha subunit category, upon activation, the subunit can
directly regulate protein kinases, phospholipase C (PLC), and Rho A GTPases (Luttrell
2008). For instance, when an agonist binds to a receptor coupled to a G, protein, its alpha
subunit (as) activates adenylyl cyclase enzyme to make the second messenger molecule
cycle adenosine monophosphate (cAMP). This cAMP then activates Protein Kinase A
(PKA) which then phosphorylates multiple downstream pathways. In contrasts, when an
agonist binds to a receptor coupled to a Gi/o protein, its alpha subunit (ai/o) inhibits
adenylyl cyclase activity, cAMP accumulation, and PKA activation.
Like alpha subunits, the beta-gamma subunits have different isoforms (5 isoforms for the
beta subunit and 12 isoforms for the gamma subunit) (Luttrell 2008). Beta-gamma
subunits regulate pathways important for cellular homeostasis and receptor activity. For
instance, beta-gamma subunits released from the G, playa major role in ion channel
regulation of the Na+/K+ and Ca2+ channels in cells. These subunits also enhance receptor
desensitization by interacting with the G protein Receptor Kinase (GRK)'s C-terminus
(Muller 1993, Pitcher 1992, Smrcka 2008).
1.1.3 Desensitization
6Desensitization is the process of a receptor no longer responding to an extracellular
stimulus, such as an agonist binding to it. Usually following this is a reduction of the
number of receptors exposed to extracellular of the cell. Reducing the number of
receptors exposed to the extracellular, gives the cell a regulatory method of controlling its
response to extracellular stimuli such as biogenic amines, hormones, or peptides.
Desensitization can occur through activation of several proteins: Regulators of G protein
Signaling (RGS), Protein Kinases (PKs), G protein Receptor Kinases (GRKs) and
arrestins.
Regulators of G protein Signaling (RGS) are proteins that regulating G protein activity
through direct interaction with the alpha subunit. As illustrated in the figure below, G
protein receptors are in equilibrium between active conformation with GTP bound and
inactive conformation with the GDP bound. The presence of an agonist favor's the
receptors G-protein active conformation whereas the presence of RGS favors the
receptor's inactive conformation. RGSs work by catalyzing GTP hydrolysis activity. This
results in the alpha-subunit to release the GTP back to the extracellular and to be once
again bound to the GDP. The now GDP-bound alpha subunit is able to rebind with the
beta-gamma subunit. The rebound G-protein is now inactive and couples back to the
receptor(Chasse 2003, Helper 2003).
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Figure 3: RGS catalyzing the GPCR inactivation. The presence ofGTPase shifts the equilibrium of activation (GTP
form) and inactivation (GDP form) to the inactivation form. SOURCE FOR IMAGE: Chasse, Scott A., and Henrik G.
Dohlman. "RGS proteins: G protein-coupled receptors meet their match." Assay and drug development technologies 1.2
(2003): 357-364. .
Protein Kinase A (PKA) also initiates desensitization and promotes GPCR inactivation.
The kinase phosphorylates the serines and threonines at the C-terminus of a GPCR
receptor (Lohse 1996, Herbst 2004). This phosphorylation leads to a conformational
change of the receptor which prevents it from interacting with extracellular agonist (Kelly
2008).
Like PKA, G protein Receptor Kinases (GRKs) initiate desensitization by
phosphorylating the receptor. GRKs have seven isoforms. GRKs 1 and 7 are solely found
in ocular tissue which contrasts with GRK 2 and GRK 3's ubiquity in numerous tissue
types. GRKs 5-6 are found in neuronal tissue and GRK 4 is found in the male testes
8(Pitcher 2012, Reiter 2006). Regardless of their location, when the GRK phosphorylates a
serine or threonine at C-terminus of the activated receptor it causes the adaptor protein
beta-arrestin to be recruited to the receptor. The GRK's N- and C- termini are also
important for recoupling the G, and G Wy subunits (Muller 1993).
What is interesting is that the serines or threonines targeted by the GRKs are different
than the ones PKA target (Cho 2007). So far, there is not much information on what
factors make a receptor more prone to undergo PKA-induced or GRK-induced
desensitization but it is a research topic that shows promise in further unmasking the
specifics of GPCR mechanism. Figure 4 below summarizes PKA- and GRK- mediated
desensitization.
9B
Figure 4 PKA and GRK induced desensitization of GPCR receptors. For both processes of desensitization, agonist-
occupation of the GPCR is important for the start of it. (A), the G protein Receptor Kinase (GRK) phosphorylates the
receptor. This phosphorylation recruits the beta-arrestin protein to the receptor and inhibits further activation of the
receptor through changing its conformation. (B) Protein Kinase A (PKA) will also phosphorylate the C-terminus of the
receptor but at different serines and threonines. This phosphorylated receptor then becomes internalized SOURCE FOR
IMAGE: Kelly, E., Christopher P. Bailey, and G. Henderson. "Agonist-selective mechanisms ofGPCR
desensitization." Britishjournal ofpharmacology 153.S I (2008): S379-S388.
As previously stated, GRK's phosphorylation initiates the recruitment of beta-arrest in to
the receptor. Beta-arrestins are a part of a group of proteins known as arrestins (Lohse
1990, Claing 2002). In total there are four isoforms of arrestin: arrestin 1 and arrestin 4
are found primarily in the eye whereas arrestin 2 (also known as beta-arrestin 1) and
arrestin 3 (also known as beta-arrestin 2) are recruited to GPCRs in a variety of cells
(Goodman 1992).
After GRKs phosphorylate a GPCR, beta-arrestins move to the receptor's phosphorylated
C-terminus region. Once attached to the receptor, beta-arrestins will recruit adaptor
10
protein 2 (AP2) and clathrin to aid in the receptor's internalization and initiate the process
of clathrin coated pit formation. The ability of beta-arrest ins to bind to multiple proteins,
characterizes them as scaffold proteins. Beta-arrestins change the receptor's conformation
so that it cannot interact with the G-proteins. This prevents further G-protein subunit
activity, reducing G protein signaling. Once formation of the clathrin coated pit is
completed (and is now a clathrin coated vesicle), internalization (endocytosis) of the pit
with desensitized receptors and beta-arrestins occurs (Shenoy 2006).
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Figure 5: Process of desensitization and c1athrin-mediated endocytosis involving beta-arrestin proteins. Here the
receptor beta-adrenergic is used as an example. The phosphorylation of the receptor by GRK recruits beta-arrestin.
Beta-arrestin, being a scaffold protein, binds AP2 and c1athrin simultaneously then dynamin fission separates the pit
from the plasma membrane and the vesicle undergoes endocytosis. SOURCE FOR IMAGE: Pierce, Kristen L., and
Robert J. Lefkowitz, "Classical and new roles of ~-arrestins in the regulation of G protein-coupled receptors." Nature
Reviews Neuroscience 2.10 (2001): 727-733.
Group A and Group B GPCRs have been shown to have different affinities for beta-
arrestins. Group A GCPRs have a stronger affinity for beta-arrestin 2 than beta-arrestin 1,
and after internalization, the receptor easily dissociates from the beta-arrestin protein.
This allows the GPCRs to recycle back to the plasma membrane. In contrast, the Group B
11
GPCRs have strong affinity for both beta-arrestin1 and beta-arrestin 2. These receptors
take a longer time to be recycled back to the plasma membrane (Sorkin 2002, Sorkin
2009). This process of internalization is also known as endocytosis. Endocytosis is the
process of fluid (pinocytosis) or solid material (phagocytosis) entering the cell as a
vesicle (Sorkin 2002, Sorkin 2009). Within pinocytosis, several categories of endocytosis
are based on the coating of the vesicle itself. Among these categories are clathrin-
dependent endocytosis and clathrin-independent endocytosis.
1.2 Sympathetic Nervous System and Adrenergic Receptors
Adrenergic receptors are GPCR Group A receptors that are found in a variety of cells but
are highly populated in the brain, myocardial tissue, kidneys, lungs, and arteries (Piascik
2001). When the body responds to stress, the sympathetic nervous system is activated and
catecholamines epinephrine and norepinephrine are produced. The catecholamines target
these receptors and the overall goal of receptors' activation is to provide the energy,
blood supply, and oxygen necessary for an organism to appropriately handle the stressful
situation as the figure below shows. The physiological responses of these receptors when
bound to catecholamines include vasodilation of the arteries in the skeletal muscles ,
increase in heart rate, and increase in blood pressure (Perez 2001, Islami 2014). In this
introduction, the focus will be on beta-adrenergic receptors.
12
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Figure 6: Epinephrine and nor-epinephrine activation of beta-adrenergic receptors and their affect on the
cardiovascular system and energy metabolism. SOURCE OF IMAGE:
http://www.britannica.comlEBchecked/medialI24084IEpinephrine-binds-to-a-type-of-G protein-coup led-receptor
1.2.1 Beta-adrenergic receptors
Beta-adrenergic receptors are highly expressed in the heart, skeletal muscles, and lungs.
In the heart, Beta-adrenergic 1 receptors are the primary subset of beta-adrenergic
receptors found in cardiovascular muscle tissue and outnumber beta-adrenergic 2
receptors four to one (Lefkowitz, 2000, Watcher 2012, Brooded 2006). They are found
in the right atrium and control the heart rate of myocardial tissue. Both receptor
subtypes are coupled to G, proteins and upon activation will increase heart rate and heart
muscle contraction. When the alpha subunit of the Gs protein is released upon beta-
adrenergic receptors activation by epinephrine and norepinephrine; it activates adenylyl
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cyclase and the cAMP accumulation results in PKA activation. The activation of this
kinase leads to phosphorylation of L-type calcium channels which causes Ca2+ influx in
the sarcoplasmic reticulum. The phospholamban (sarcomere reticulum) then releases
calcium ions which affects the activity of troponin I, ryanodine receptors, myosin
binding protein-C, and protein phosphatase Inhibitor-l (PPI) as shown in Figure 7
below. The activity of the troponin I, ryanodine receptors, myosin binding protein-C
proteins and receptors leads to cardiomyocyte contraction whereas the activity of PPI-I
provides a negative feedback regulation of cardiomyocyte contraction (DeWire 2011,
Lohse 2003).
Figure 7: Molecular mechanism muscle contraction in the heart. SOURCE OF Lohse, Martin J., Stefan
Engelhardt, and Thomas Eschenhagen. "What is the role of~-adrenergic signaling in heart failure?" Circulation
research 93.10 (2003): 896-906.
Beta-adrenergic 2 receptors can also be found in heart and regulate cardiomyocyte
contraction as previously described. In addition, these receptors are also highly
expressed in striated muscle tissue, 01 tract, and the human eye (Watcher 2012). It is the
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beta-adrenergic 2 receptors' presence in multiple tissues that makes them of interest to
research focused on GPCR activity. For instance, in the heart, the adrenergic receptors
are involved in increasing muscle contractions whereas in the lungs, activation of beta-
adrenergic 2 receptors promotes vasodilation of blood vessels. This vasodilation helps
promote oxygen intake into the lungs.
1.3 Clinical treatments that target beta-adrenergic receptors
Chronic activation of beta-adrenergic receptors has been linked to cardiovascular diseases
such as congestive heart failure, angina pectoris, and left ventricular hypertrophy. The
heart's contraction force (inotropic) and the rate (chronotropic) are increased and long-
term, this leads to stiffening of the left ventricle walls and thinning of the arteries that
affect the heart's ability to pump out adequate amount of oxygen-rich blood to the body.
The activation of the beta-adrenergic receptors by high toxic levels of catecholamine
causes chronic activation of the receptors' G, protein. Activation of this protein promotes
apoptosis of the cells which long-term can lead to tissue damage, and detrimental tissue
remodeling (hypertrophy), and clinically lead to the progression of cardiovascular
diseases (Bristol 2000). Beta-adrenergic receptor 1 and 2 are affected differently by
chronic activation. For beta-adrenergic-I receptors, chronic activation results in a
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decreased population of these receptors in the cells. Beta-adrenergic 1 receptors usually
populate myocardial tissue 4: 1 in comparison to beta-adrenergic 2 receptors; however
chronic activation of the receptors reduces this ratio of the receptors to be roughly the
same amount (3:2) (DeWire 2011. Watcher 2012). This change in beta-adrenergic 1
population indicates that for these receptors, chronic activation leads to increased
desensitization and internalization. In contrast, beta-adrenergic 2 receptors' rate of
internalization does not change. Instead these receptors switch their G protein coupling
from G, to GilD to occur (Daaka 1997). During desensitization of the beta-adrenergic 2
receptor, PKA phosphorylates the receptor at the Serine 262 in its C-terminus (Daaka
1997). This causes the uncoupling of the Gs protein from beta-adrenergic 2 receptor
allowing the coupling of the receptor to the GilD protein to occur. The GilD protein inhibits
cAMP activity as well as other downstream pathways that are dependent on the presence
of cAMP and PKA phosphorylation. One consequence of this switch is that the GilD
protein activates the ERK pathway (Daaka 1997). Research has shown that the activation
of ERK by beta-adrenergic 2 receptor post G protein switch may actually serve as a
cardioprotective mechanism to counter the apoptosis effects of the G, protein (Noma
2007).
Clinically, drugs targeting beta-adrenergic receptors known as beta-blockers are
prescribed to counter the effects of receptor activation. Clinical drugs are categorized by
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their ability to activate or inhibit the activation of pathways. Agonist, are typically able to
activate pathways and antagonists tend to inhibit those same pathways. Beta-blockers are
categorized as antagonists that bind to these receptors and block epinephrine and
norepinephrine from interacting with them. The idea is that by blocking beta-adrenergic
receptors' active site, catecholamines would be unable to bind with the receptors and
activate pathways linked to the cardiovascular diseases. The Os induced receptor
desensitization and apoptosis activity is also prevented by these beta blockers.
1.4 Beta-blockers
The first drug used to target the beta-adrenergic receptors was dichloroisoproterenol
made in 1958 by Eli Lilly & Co (Watcher 2012). Since then there have been over thirty
beta-blockers made specifically for treating cardiovascular diseases. There are three
categories of beta blockers. The "first generation" beta blockers include propanolol,
pindolol, and alprenolol and all of them block both beta-adrenergic receptors with the
same affinity. In contrast, "second generation" beta-blockers which include metoprolol,
bisoprolol and atenolol are all highly selective for beta-adrenergic-I receptors. Third
generation beta blockers are nonselective for the beta-adrenergic receptors but in
addition also target alpha-adrenergic receptors responsible for artery vasodilation
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(Mansoor 2009, Brodde 2007). Examples of the third generation beta-blockers are
carvedilol, labetalol, and bucindolol (Broode 2007 , DeWire 2011).
Although beta-blockers are categorized as antagonists, functionally, beta-blockers are
also categorized by the extent they inhibit cAMP production in cells. For example,
propanolol is categorized as an inverse agonist and labetalol is categorized as a partial
agonist; propanolol is able to lower cAMP levels in the cell lower than Labetolol
(Ganlandarin 2006).
1.4.1 Traditional view of beta-blockers' activity with adrenergic receptors
When beta-blockers were initially identified, the prevailing view was that the receptors
themselves only had two conformations: active and inactive. The epinephrine or
norepinephrine's interaction with the beta-adrenergic receptors favored the receptor's
active conformation. Whereas the beta-blockers would maintain the beta-adrenergic
receptor's inactive conformation by blocking the catecholamines access to the receptors'
active site as the Figure 8 below shows (Patel 2010).
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Figure 8: Mechanism of beta-blockers SOURCE FOR IMAGE:
http://marianuniversityscienceblog.wordpress.com/20 10110/15/beta-blockers- function-and-effectsl
Even with the success of these antagonists, clinicians and researchers found that these
beta-blockers were not equally effective in treating the same cardiovascular disease. For
instance out of all of the beta-blockers currently in the market, bisprodol, mesprolol, and
carvedilol are the only ones that have been FDA approved for use to treat chronic heart
disease (Watcher 2012, Lohse 2003).
1.4.2 Functional Selectivity
The research findings of Dr. Sengolese Galandrin ,Dr. Alem Kahsai, as well as others
showed that the perceived mechanism of action for beta-blockers of solely as an
antagonists was not correct. For instance, one study showed that beta-blockers such as
labetalol, alprendolol, carvedilol, propanolol, and bucindolol are able to activate ERK
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pathway while simultaneously inhibiting cAMP accumulation (Galandrin 2006). Dr.
Alem Kahsai's lab group showed that these beta-blockers can activate ERK while
simultaneously inhibiting cAMP accumulation in the cells (Kahsai 2012). The works of
Dr. Kahsai, Dr. Galandrin, and others, questions the validity of the idea two-
conformation theory being a true representative of GPCR receptor activity. Instead, these
researchers suggest that receptors may have multiple active conformations (multiple
conformation theory) (Patel 2010). The figure below shows a comparison between the
two model (linear efficacy) and pluridemensional efficacy (multiple conformation model).
The ability of a ligand to bind to a receptor and affect its conformation so that it
selectively activates or inactivates different pathways is known as functional selectivity.
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Figure 9 Comparison of Two-conformation change vs. Multiple-conformation receptor changes (Functional selectivity)
A) Former two-conformation change when ligand binds to the receptor B) The current functional selectivity theory that
ligands are capable of activating and inhibiting pathways simultaneously. SOURCE OF IMAGE: Patel, Chetan B.,
Nabila Noor, and Howard A. Rockman. "Functional selectivity in adrenergic and angiotensin signaling
systems." Molecular pharmacology 78.6 (20 I0): 983-992.
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Drugs that display functional selectivity shows promise in pharmaceutical research and
clinical studies. Researchers will be able to study these drugs' selectivity and use the
knowledge to create more ideal drugs that will be able to more effectively alter the
pathways that lead to the ailments (van der Westhuizen 2014). Functional selectivity
(also known as ligand bias) has also recently shown to be important in drug taxonomy
because now researchers know that that same drug can have different affects on different
pathways. For instance, a recent study looked into categorizing drugs based on how many
pathways a beta-blocker was capable of activating. Although labetalol and carvedilol are
both characterized as third generation beta-blockers, based on their pathway activation
ability, labetalol in the study is categorized as a Group III drug because it has agonist
characteristics for both cAMP and ERK pathways whereas carvedilol is categorized as a
Group IV drug in the study because it only shows agonist characteristic for the ERK
pathway (van der Westhuizen 2014).
The research done by these scientists has also revealed the complexity of how these beta-
blockers are activating different pathways, particularly ERK activation. One study using
beta-adrenergic 1 receptors found that isoproterenol and bucindolol both activate ERK
through src-induced EGFR transactivation. However, this same study showed that only
isoproterenol activates ERK using G protein alpha and beta-gamma subunits in addition
to EGFR transactivation. Bucindolol and propanolol (also used in this study) were found
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to activate ERK through a G protein independent process that's also independent of beta-
arrestin activity (Galandrin 2008).
The table below summarizes the current links of functional selectivity with select beta-
blockers when they bound with beta-adrenergic-1 receptors. With more investigation into
the mechanism of action of these and other beta-blockers, hopefully certain
characteristics of these beta-blockers that are predictive of their molecular mechanism of
action will be uncovered.
Table 1: Summary of research findings of selected beta-blockers ERK pathway
activation when bound to Beta-adrenergic 1 receptors
Name of Generatio cAMP Categorizatio Clinical Use Source(s)
Beta- n of beta- categorizatio n based on (Source: van
blocker blocker n ERK der
(1,2,3) Westhuizen et
al, 2014)
Alprenolol 1 Partial agonist Partial agonist Hypertension, Kim 2008
(EGFR angina Galandrin
transactivation pectoris, 2008
and beta- arrhythmia
arrestin)
Bucindolo 1 Partial agonist Partial agonist Heart failure Galandrin
I (Src activation) 2006,200
8
Carvedilol 3 Partial inverse Partial agonist Hypertension, Wisler
agonist (beta-arrestin Ischemic 2007,
and EGFR Heart Disease, Kim 2008
transactivation) heart failure, Galandrin
post- 2008
Myocardial
infarction
Labetalol 3 Partial agonist Partial agonist Hypertension, Galandrin
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(unknown hypertensive 2008
pathway its emergencies
targeting)
Propanolol 1 Inverse Partial agonist Hypertension, Galandrin
agonist (unknown angina 2008
pathway its pectoris ,atrial
targeting) arrhythmia,
portal
hypertension,
anxiety,
tremor,
thyrotoxicosis
, migraine
1.5 Endocytosis
One pathway that can be affected by functional selectivity is the process a receptor takes
to undergo receptor internalization also known as endocytosis. Subcategories of
endocytosis are phagocytosis (engulfing of solid material) or pinocytosis (engulfing of
fluid material) which most GPCRs undergo. The most widely known subcategory of
pinocytosis is clathrin-dependent endocytosis.
Both beta-adrenergic receptors undergo clathrin-mediated endocytosis. In addition, beta-
adrenergic 1 receptors show less dependency on this process for endocytosis than beta-
adrenergic 2 receptors. The beta-blockers that are more selective for beta-adrenergic 1
than beta-adrenergic 2 receptors could potentially dictate which process of endocytosis
beta-adrenergic 1 receptors undergo. A clear understanding of the complexities of
clathrin-mediated and clathrin-independent endocytosis could provide insight into how
the ligand bias of beta-blockers and other drugs can affect receptor internalization activity.
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1.5.1 Clathrin-Mediated Endocytosis
Ironically, clathrin is not the key protein for clathrin-mediated endocytosis to occur.
Clathrin recruitment and organization is dependent on proteins that link the receptors to
the clathrin known as adaptor proteins. Examples of adaptor proteins involved in this
process are heterotertrametric adaptor proteins such as Adaptor Protein 1-4. These
proteins have two large subunits (can be alpha, beta, or gamma) also known as adaptins,
one mu-subunit and one sigma-subunit. It is the two large adaptin subunits that have a
recognition sequence for clathrin recruitment. Although monomeric adaptors known as
GGA (golgi-Iocalizing gamma adaptin ear domain homology, ART-bind proteins) are
also found to be important for clathrin-recruitment, the most common adaptor protein
found coordinating clathrin oligomerization at the plasma membrane are AP2s
(McMahon 2011). Adaptor protein- 2s have a recognition sequence in their beta and
gamma subunits that aid in the stacking of the clathrin proteins. Once the adaptor proteins
surround the receptors to be internalized, the clathrin are recruited and oligormize to form
clathrin- coated pits (Claing 2002). Clathrin is described as a trimer protein that
surrounds the intracellular region of the material to be internalized as a vesicle (Traub
2005). The accumulation of clathrin and adaptor proteins leads to a pit formation that
includes in it the receptor(s) to be internalized. Beta-arrestins are also adaptor proteins
and assists in clathrin-dependent endocytosis by binding to Adaptor Protein 2 (AP2) and
c1athrin as Figure 10 below shows.
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Figure 10: Beta-arrestin involvement in receptor internalization ofGPCR receptor. SOURCE FOR IMAGE: Reiter,
Eric, and Robert 1. Lefkowitz. "GRKs and B-arrestins: roles in receptor silencing, trafficking and signaling." Trends in
endocrinology & metabolism 17.4 (2006): 159-165.
The final step in endocytosis involves budding off of the clathrin-coated pit which is
done by the GTPase protein dynamin. Dynamin separates the vesicle from the plasma
membrane in a process called scission (Claing 2002). After budding, the vesicle can
either undergo degradation or the receptor(s) are modified and recycled back to the
plasma membrane (Claing 2002). The phase when a receptor is recycled is determined by
which GTPases are available to transport the receptor back to the plasma membrane. For
instance, during early stage endocytosis, GTPases Rabs 4 or 5 bind to the vesicle and
help initiate recycling of the receptors back to the plasma membrane. Usually Group A
GPCR receptors take this route back to the plasma membrane (Sorkin 2009). If it is late
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stage endocytosis, GTPase Rab 11 attaches to the vesicle and helps initiate receptor
recycling back to the plasma membrane (Sorkin 2009). Group C GPCR receptors tend to
take this route back to the plasma membrane In contrast, if Rab 7 is attached to the
vesicle, the vesicle will usually undergo chemical changes such as increased acidity in
preparation of lysosome degradation (Sorkin 2009). Figure 11 below shows the process
of endocytosis.
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Figure 11: Clathrin mediated endocytosis showing early and late endocytosis and the Rab proteins that determine
receptor fate. SOURCE FOR IMAGE: Sorkin, Alexander, and Mark von Zastrow. "Endocytosis and signalling:
intertwining molecular networks." Nature reviews Molecular cell biology 10.9 (2009): 609-622.
1.5.2 Cholesterol Lipid Rafts and other processes of endocytosis
As previously stated, a study with beta-adrenergic 1 receptors found that its rate of
endocytosis is dependent on the presence of cholesterol lipid rafts. This 2004 study
showed that when the cholesterol-binding agent M~CD removed the cholesterol lipid-
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rafts near the cell's plasma membrane, the rate of beta-adrenergic 1receptors undergoing
endocytosis decreased (Ostrom 2004, Steinberg 2004). This finding suggests that in
addition to clathrin-mediated endocytosis, beta-adrenergic 1 receptors may be dependent
on clathrin-independent lipid rafts for endocytosis.
Lipid rafts consists of sphingolipid-enriched domains and cholesterol that help in receptor
internalization (Kirkham 2005, Ostrom 2004). Specifically the phosphoinositides (PIP2),
found in these lipid rafts are important for vesicle formation (Ostrom 2004, Claing 2002).
The invagination occurs due to the weight of the lipid rafts as they accumulate under the
plasma membrane section with the desensitized GPCRs (Pelkman 2005). Like clathrin-
mediated endocytosis, budding of the vesicle involves GTPase the dynamin II for
endocytosis.
Receptor undergoing endocytosis through lipid raft endocytosis avoid possible
degradation by bypassing Rabs 4,5, 7, and 11. Unlike clathrin-mediated endocytosis,
lipid rafts used for endocytosis are not as tightly regulated. By avoiding the GTPases, the
lipid-raft created could promote quicker receptor recycling. In addition, cholesterol rafts
do help activate Na+ and K+ channels and calcium signaling (Pelkman 2005). Since, for
beta-adrenergic receptors, regulation of calcium signaling through lipid rafts would
further promote the muscular contractions it initiates, this could be another benefit of the
receptor undergoing lipid raft mediated endocytosis.
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Beta-adrenergic 2 receptors rarely use lipid-rafts for endocytosis, however lipid-rafts may
be important for their activity (Allen 2005). OPCRs that are capable of 0 protein
switching like beta-adrenergic 2 receptors have been reported to use lipid rafts as a
docking base to switch their 0 protein coupling (Ostrom 2004, Allen2005). 0 protein
switching is when the receptor uncouples from one subset of 0 protein (such as Os) in
order to couple with another 0 protein subset (such as Oi/o).0 protein switching is
usually initiated by PKA phosphorylation and as a result there's a possibility that lipid
raft formation may be regulated by this kinase's activity and the raft oligiomerization
may serve as a preparatory step for receptor internalization (Helksman 2005, Ostrom
2004). Another reason why lipid-raft formation may be regulated by PKA
phosphorylation is because lipid rafts are unable to oligermize in the presence of beta-
arrestins. As previously discussed, beta-arrestins' recruitment to the plasma membrane is
connected to ORK phosphorylation of the receptor.
A subset of lipid rafts called caveolae is commonly found in myocardial tissue,
pulmonary tissue and the kidneys thus showing strong connections between their
formation and beta-adrenergic receptor activity (Michel 2007). The three caveolin
isoforms oligermize to form the caveolae pits. One study showed that low levels of
caveolin-3 is shown to causes left-ventricular hypertrophy and increase MAPK pathway
activity whereas high levels of caveolin-3 also cause cardiac hypertrophy(Michel 2007).
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1.6 Activation ofERK pathway
For GPCRs and other classes of receptors, endocytosis does not only inhibit the
activation of signal transduction pathways but activates other pathways. A highly
investigated pathway that can be activated during endocytosis is the pathway that leads to
the activation of Extracellular Receptor Kinase (ERK). As discussed earlier, functional
selectivity can affect the activation of different pathways. In the field of cardiology, ERK
activation is of interest because its ability to reverse cell death of myocardial cells
common in patients with chronic heart failure and other cardiac diseases (also known as
cardioprotective effect).Drugs such as alprendolol and carvedilol have been shown to
selectively activate this kinase while simultaneously inhibiting cAMP pathway, giving
insight to why they are effective in treating certain cardiovascular diseases.
The pathway involved in activating ERK includes the docking proteins Grb and SOS and
the GTPases Ras, Raf, and MEK (Ostrom 2004). This protein cascade is one of the three
pathways categorized as being a part of the Mitogen Activated Protein Kinase (MAPK)
pathways. Unlike the c-Jun (cancer- Jun) and p38 pathways that are also in this group,
ERK is highly researched due to its necessity for maintenance of cell growth and
differentiation (May 2008). The other two pathways, c-Jun and p38, are primarily
activated during cell-stress-related apoptosis or inflammation (Murphy 2009). Figure 12
shows a chart of all three MAPK pathways and the proteins they activate. ERK
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phosphorylation is last in a protein cascade involving different proteins. Once the
Epidermal Growth Factor Receptor (EGFR) is activated and dimerizes, the Sos (sons of
sevenless) protein is activated and phosphorylates the GTPase Ras (Rat sarcoma). Ras
then phosphorylates a Raf (Rapidly Accelerated Fibrosarcoma) isoform, which then
activates MEK (Mitogen-activated protein kinase/ERK kinase). MEK is the kinase that
phosphorylates ERK (May 2008).
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Figure 12 MAPK Kinase families ERK, p38, c-Jun. SOURCE FOR IMAGE: Cargnello, Marie, and Philippe P. Roux.
"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases." Microbiology and
Molecular Biology Reviews 75.1 (2011): 50-83.
The numerous activators of the ERK signaling pathway also make it an important
pathway to study for functional selectivity. The focus here will be on three of these
pathways that beta-blockers have been shown to use to phosphorylate ERK: EGFR
pathway, G protein mediated activation, and beta-arrestin mediated activation.
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1.6.1 EGFR transactivation
Epidermal Growth Factor Receptor (EGFR) is a tyrosine-kinase class receptor that is
directly linked to the ERK pathway as Figure 13 shows below.
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Figure 13: EGFR ERK signaling pathway. SOURCE FOR IMAGE: Schlesinger, Joseph. "Cell signaling by receptor
tyrosine kinases." Cell 103.2 (2000): 211-225.
As the receptor's name suggests, this cascade regulates the growth and proliferation of
the cell. In addition to this role, reports have shown that this receptor is also capable of
moderating cell adhesion, migration, and apoptosis (Herbst 2004). Activation of tyrosine-
kinase receptors is similar to Group C GPCRs in that the monomers of the receptor
dimerize upon activation by an agonist (Herbst 2004). For EGFR, its physiological
agonist is the Epidermal Growth Factor (EGF). Once the receptor is activated, it
I
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phosphorylates a kinase called Src which then activates the Sos-Grb2 complex and
activates the protein cascade that leads to ERK phosphorylation and activation. The
overexpression ofEGF and Src together has been linked to high increases in DNA
synthesis and tumor growth (Abram 1990).
Beta-adrenergic receptors can activate ERK through EGFR transactivation as Figure 14
below shows. EGFR transactivation occurs when activation of a GPCR by a ligand
results in activation of the EGFR and its signaling pathway although no ligand binds
directly to the receptor. EGFR transactivation by beta-adrenergic receptors is dependent
on beta-arrestin and Src kinase activity (Maudsley 2000). Src is key in this co-
activation. Beta-arrestin recruits this kinase to the plasma membrane when it itself is
recruited to the receptor by GRK. The Src kinase then activates EGFR by
phosphorylating the EGFR receptor (Kim 2008, Maudsley 2000).
Figure 14: The process ofEGFR transactivation by beta-adrenergic 2 receptors. SOURCE FOR IMAGE: The ~2-adrenergic
receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the
epidermal growth factor receptor." Journal of Biological Chemistry 275.13 (2000): 9572-9580.
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It is not completely understood what factors promote EGFR transactivation to occur but
one possibility is that it is dependent on GRK- induced desensitization (Kim 2008).
GRKs 5 and 6 have been linked to increase ERK phosphorylation in addition to receptor
desensitization in contrast to GRK 2 which is found to not increase ERK levels when it
phosphorylates the
receptor for desensitization (Noma 2007, Smrcka 2008). In addition, the 2000 Dr. Stuart
Maudsley study shows that beta-adrenergic induced EGFR transactivation was sensitive
to clathrin-mediated endocytosis further supporting the idea that the kinase that
desensitizes the receptor also determines how the receptor becomes internalized and what
pathways it will activate post-endocytosis. Currently no beta-blockers that target beta-
adrenergic 2 receptors have been linked to this transactivation activity; however, with
beta-adrenergic 1 receptors, carvedilol and alprendolol were found to use EGFR
transactivation to activate ERK (Kim 2008). Dr. Steven Prinster's group have provided a
possible biological basis for receptor transactivation. He suggests that transactivation
could be a way to optimize Erk-phosphorylation in the cell as well as receptor
internalization. EGFR's protein cascade directly includes Erk; GCPR desensitization
results in recruitment of beta-arrestins. Both processes alone promote Erk activation so
possibly transactivation causes a synergistic effect for Erk signaling (Prinster 2005).
1.6.2 Beta-arrestin-induced ERK activation
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Beta-arrestins are also capable of signal transduction. The process of beta-arrestin
mediated ERK activation occurs when an isomer of Raf (Raf-l), MEK 1 and ERK all
bound to beta-arrestin as Figure 15 shows below. The result of this is ERK is directly
phosphorylated by MEK 1 (Reiter 2006).
Figure 15: The process of beta-arrest in mediated endocytosis. SOURCE FOR IMAGE: Luttrell, Louis M., et a1.
"Activation and targeting of extracellular signal-regulated kinases by ~-arrestin scaffolds." Proceedings of the National
Academy of Sciences 98.5 (2001): 2449-2454
This cascade of events occurs only after a GPCR is activated by an agonist and the
receptor itself undergoes the process for desensitization which includes beta-arrestin
recruitment. Unlike the ERK activation mediated by EGFR or G proteins, when beta-
arrestin mediates ERK activation, the level of ERK signaling is not as high as the ones
induced by EGFR or G protein, however, the signal is sustained for a longer period of
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time in the cytosol. Maintaining ERK's presence in the cytosol has been found to help
prolong the activity of the cascade (Kovacs 2009, Beaulieu 2011). Beta-arrestin mediated
ERK activation also does not involve translocating the kinase into the cell nucleus for
protein transcription activation. Beta-blockers ICI 118-551 and propanolol have shown to
be dependent on beta-arrestin activity for ERK phosphorylation, specifically when they
are bound to beta-adrenergic 2 receptors (Azzi 2004).
1.6.3 G-protein switching and ERK activation
As previously discussed, G protein switching is another process that can activate ERK
(Daaka 1997). For instance, when GPCR beta-adrenergic 2 receptors undergoes G protein
switching to uncouple from the G, and couple the Giloprotein, the end result is adenylyl
cyclase activity being reduced while ERK is simultaneously activated as shown in Figure
16 below (Kirkham 2005, Smrcka 2008).
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Figure 160 protein mediated ERK activation through O-protein switching. SOURCE FOR IMAOE: Smrcka, A. V.
(2008). "0 protein beta-gamma subunits: Central mediators of 0 protein-coupled receptor signaling." Cell Molecular
Life Science 65(14): 2191-2214
1.7 The goals of this study
Beta-adrenergic1 receptors most commonly activate ERK through beta-arrestin or EGFR
transactivation. Beta-adrenergic 2 receptors commonly activate ERK through both
processes as well as G-protein switching. It is the differences in how these receptors can
activate ERK (especially in the heart where ERK activation is linked to a cardio-
protective mechanism) that draws interest to which beta-blockers are selecting for ERK
activation when bound to beta-adrenergic 1 or beta-adrenergic 2 receptors. In addition,
how the beta-blockers may be selecting for ERK activation is of great interest to
researchers.
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In comparison to beta-adrenergic 1 receptors, little research has been done with beta-
adrenergic 2 receptors to give full detail on which pathways these beta-blocker ligands
are selecting to activate ERK. The next step in the study is to determine which of the
three possible pathways the beta-blockers activate to cause the ERK phosphorylation.
In this research functional selectivity of beta-blockers when they bound to beta-
adrenergic 2 receptors was investigated. Specifically cAMP and ERK signaling were
observed. The beta-blockers used in this experiment were carvedilol, carazolol, labetalol,
alprenolol, propanolol, bucindolol and ICI 118,551. These beta-blockers were chosen
because they are a selective representative of the span of drugs classified as beta-blockers
based on how well they inhibited cAMP accumulation in comparison to full agonists.
Labetalol, alprenolol, and bucinidol are subcategorized as partial agonists; carvedilol and
carazolol are categorized as a partial inverse agonists; and propanolol and ICI 118, 551
are categorized as full inverse agonists.
To measure the effects of these beta blockers on the cAMP pathway, the beta-blockers
were introduced to HEK 293-beta- adrenergic 2 transfected cells at different
concentrations and their ability to inhibit cAMP accumulation (caused by the presence of
full agonist Isoproterenol) was observed. For the effects of the beta-blockers on ERK
phosphorylation, the beta-blockers' dependence on EGFR transactivation and clathrin
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meditated receptor internalization for ERK phosphorylation was investigated. For this
study the beta-blockers were added to HEK 293 cells expressing the beta- adrenergic 2
receptor in the presence of three clathrin mediated endocytosis inhibitors and two
inhibitors specific for EGFR transactivation. The ERK signaling of these beta-blockers
was compared to full agonist isoproterenol as well as control ERK levels in the absence
of any inhibitors. This was done to determine if these beta-blockers were displaying
partial agonist characteristics with respect to the ERK pathway as well as if the beta-
blockers' ERK phosphorylation is dependent on either EGFR transactivation or clathrin-
mediated receptor internalization.
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Chapter Two: Materials and Methods
2.1 Adrenergic Ligands and Inhibitors
ICI 118,551 hydrochloride (ICI), Alprenolol hydrochloride (Alp), Isoproterenol
hydrochloride (Iso), (S)-( -) Propranolol hydrochloride (Prop), Carvedilol (Carv), and
Bucindolol (Buc) were all purchased through Torcris (Bristol, United Kingdom).
Labetalol (Lab) was purchased from Sigma-Aldreich (St. Louis, Missouri). Clathrin-
mediated endocytosis inhibitor Chlorpromazine (CPZ), EGFR inhibitor AG 1478, and Src
kinase inhibitor PP2 were all purchased from Sigma Aldrich (St. Louis, Missouri), the
inhibitor Dynasore was purchased from Ascent Scientific (now Abeam Scientific)
(Cambridge,Massachusetts). The sucrose for the 0.45M hypertonic sucrose media
solution was purchased from VWR International (Randor, Pennsylvania).
2.1.1 Preparation of Adrenergic Ligands and Inhibitors
All adrenergic ligands were purchased in powder form from their various companies. In
order to preserve the amount of drugs, stock solutions of 10mM were made. All of the
drugs except for Bucindolol used ddH20 as their solvent. Bucindolol uses DMSO as its
solvent. For the inhibitors AG 1478, PP2, CPZ and Dynasore used in this study, they were
purchased in their powder form from their various companies. Each inhibitor amount was
preserved by making 5mM stock solutions of each. For all inhibitors, except Dynasore,
ddH20 was the solvent used. For Dynasore, DMSO was the solvent used for its stock
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solutions. All compounds were diluted from their stock solution to DMEM (at various
concentrations for cAMP assay) or serum free DMEM (for ERK assay) or 0.45M sucrose
(for ERK assay but solely for cells with sucrose DMEM media).
2.2 Cell Culture and Transfections
Human Embryonic Kidney (HEK 293) cell line was used to transfect with plasmids
coding for human beta-adrenergic 2 receptors. HEK 293 cells stably expressing beta-
adrenergic 2 receptors were confirmed by radioligand binding assay. The cell line
colonies that expressed the highest levels of human beta-adrenergic 2 receptors were
used in the study (CLAI and #2). Isoproterenol was the ligand used in this assay. The
density of the receptors expressed in the cell line was important for the detection of
downstream pathway activity of partial agonists and inverse agonists when they are
bound to the receptors. The cells were already transfected and checked for beta-
adrenergic 2 receptor density at the time of my research thanks to the work of Subhrajit
Bhattacharya and Ross Blankenship.
2.3 cAMP accumulation assay
The cAMP levels were measured through a competitive radioligand assay using
[H]3 cAMP ligand. This ligand competed with the cAMP present in the cells for binding
to Protein Kinase A. The more cAMP present in the cells, the less [H]3 cAMP ligand is
detected. Using this assay, the effect of the beta-blockers on isoproterenol-induced cAMP
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accumulation was determined. Transfected HEK-Beta-adrenergic 2 cells were plated on
poly-lysinated coated 48-well plates for 24 hours at 200,000 cells/well prior to ligand
stimulation. Concentrations of the drugs fromlE-5 to lE-8 were used in this assay to
determine each drug's concentration curve. On an ice bath, DMEM with 10% Calf
Bovine Seurm mixed with 500mM of 3-isobutyl-l-methylxanthine (IBMX) was added to
each well. The IBMX is an inhibitor of phosphodiesterase (PDE), an enzyme which
degrades cAMP by removing its phosphate group. Two-hundred and fifty microliters
(250ul) of IBMX was added to wells designated to be the control wells, 200ul for wells
designated for isoproterenol only, and 150ul for wells that will have both isoproterenol
and a beta-blocker drug so that the final concentration of IBMX for each well would be
300uM. All drugs' concentrations were added in their designated wells then incubated in
water bath set to 37°C for 5 mins. The plates were taken out of the water bath and quickly
emptied of the media before once again placed on ice. Trichloroacetate (TCA) at 3%
concentration was then added to each well at 200ul per well to fix the cAMP that is in the
cells by stabilizing the compound. The plate was placed overnight in a refrigerator at 4°C.
The next day the TCA treated lysates were counted using IX cAMP binding buffer
(100mM Tris HCI at pH 7.4 (VWR International, LLC; Cat# BDH4500-5KGP), 100mM
NaCI, 5mM EDTA solution [EDTA crystals (VWR international; Cat# VW 1474-01),
ddH20]),partially purified protein kinase A, and [H]3 cAMP (Perkin Elmer Lot# 622877).
The partially purified Protein Kinase buffer (Kinase buffer) contains PKA protein
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extracts from adrenal glands added to 150ml of cAMP binding buffer. This allows for the
detection of the cAMP in the cells based on how well they compete with the radioligand
at different concentrations. Twenty-five microliters of hot cAMP diluted with cAMP
binding buffer was added to the vial at 25ul aliquots. Lastly, 2ml of Kinase buffer/cAMP
binding buffer solution was added. This along with the samples used as a standard curve
for the assay, were incubated for two hours at 4°C. The standard curve was made by
using 5mM cAMP stock solution and doing serial dilutions at concentrations 300pmol to
O.OOlpmol. Because the concentrations in the standard curve are known, this curve is
used to help determine the cAMP concentrations from the drug-treated cells.
Both the samples used to create a standard curve and the samples that were treated
with beta-blockers were then harvested using the Perkin Elmer Harvesting apparatus. The
glass filters in the channels were first washed with cold Wash buffer made from 10mM
Tris-HCI and 0.9% w/v ofNaCI, diluted with 15L of ddlI-Oand set to a pH of 7.4. A
clean filter paper was used for Harvesting of each set. The set of vials with the TCA
lysates were ran separately from the ones with the standard dilations. Each set was ran on
the Harvestor two times before removing the filter, the circular discs made from the
harvesting process were removed from the filter paper, then each disc was individually
placed in a plastic scintillation vials using tweezers. The circular discs contains the
filtrate of bound protein samples and the 400ul of scintillation cocktail added to the
circular disc that is in the vial, is used to heighted the [H]3 cAMP signal. These vials were
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capped, set into racks and flagged with Packard Protocol 17 and counted on the Tri-Carb
3100R liquid scintillation counter (Perkin Elmer, Waltham, MA). The data generated
from this program was then analyzed using Graph-Pad Prism 4.0 software.
2.4 ERK-stimulation assay using inhibitors of clathrin-mediated endocytosis
HEK-~A2 cells were plated in 24-well plates coated with poly-lysine overnight prior to
serum starvation (DMEM media with 10% Calf Bovine Serum). To prep the cells for
serum starvation, the DMEM media is removed from the cells. The cells are then washed
three times with serum free media (DMEM without the 10% calf bovine serum) to
remove the presence of serum from the cells. This task is necessary because serum
contains growth factors and those growth factors can activate of other receptors in the
HEK-~A2 cells which can cause ERK activation. This tasks helps to reduce ERK to most
basal levels before drug stimulation is done. After the three washes, the serum free media
is then added to the cells and incubated in the 37°C incubator for 6 hours. At thirty
minutes prior to the end of the drug stimulation time, clathrin-mediated endocytosis
inhibitors 10uM CPZ (10mM stock solution of Chlorpromazine in ddH20 diluted in
Serum Free DMEM media), 10uM Dynasore (50mM stock solution of Dynasore in
DMSO diluted in Serum Free DMEM media), and 0.45M sucrose (Sucrose crystals
[VWR International; Cat # VWI498-04] diluted in Serum Free DMEM media) were
added to the designated cells. During drug stimulation, all the drugs were diluted in
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DMEM then added their designated cells for a final concentration of lE-5 for each drug.
The cells were incubated for five minutes in 37°C water bath. A lysis buffer (1X
Laemmli Buffer[2% SDS, 5% 2-mercaptoehtanol, 10% glycerol,0.002% bromophenol
blue, 0.00624M Tris HCI,Check the pH and bring it to pH 6.S]) was used to stop cellular
activity and extract the ERK proteins out of the cells. The cell plate was then placed in
SO°Cwater bath for 5 minutes, then the samples were transferred to 1.5ml centrifuge
tubes before being heated in a 95°C water bath for five minutes. The samples were then
stored in -SO°C freezer.
2.4.1 ERK-stimulation assay using inhibitors of EGFR and Src activity
The same protocol is used for ERK stimulation as previously discussed. The sole
difference is that at thirty minutes prior to drug stimulation, the inhibitors of EGFR
(5mM AG147S diluted in serum free DMEM media) and Src (5mM PP2 diluted in serum
free DMEM media) are added to the designated cells.
2.5 SDS PAGE- Electrophoresis
The materials used to make the gels were one gel casting frame (BioRad), one gel casting
stand (BioRad), one gel casting short glass plate (BioRad Cat# 165330S), one gel casting
1.5mm spacer glass plate (BioRad Cat# 1653312), and one 15-well comb (BioRad
Cat#1653366). The short glass plate is fastened together with the 1.5mm spacer glass
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plate using the gel casting frame. The short glass plate is in front of the spacer glass plate.
The now fastened glasses and frame are then locked onto the gel casting stand.
For making l Oml 10% acrylamide resolving gel solution, 3.96ml of ddH20, 2.Sml of I.S
M Tris-CI, pH 8.8 Tris base (VWR International, LLC; Cat# BDH4S00-SKGP). 3.33ml
of 30% (29: 1) Bis/Acrylamide/ Acrylamide solution (lBI Scientific Lot# 12II8S0),
0.008ml of 99% N'N'N'N' -Tetramethylethylenediamine for electrophoresis(TEMED)
(Sigma Cat# 036K0694), O.lml of 10% Ammonium persulphate or APS (VWR
International; LOT# C11468), 0.1ml of 10% Sodium Dodecyl Sulphate or SDS solution
(lBI Scientific Lot# 1OL38S0) were all used.
Once the resolving gel was poured in between the fastened short glass plate and the
1.Smm spacer glass plate, 200ul of 70% isopropanolol is poured on top of the gel so that
the gel solidifies evenly. Gel solidification usually takes between twenty to thirty minutes.
During the wait time for the gel solidification, crosslinks are formed by the
Bis/ Acrylamide/ Acrylamide solution catalyzed by TEMED and APS. The crosslinks
create pores that proteins, based on their molecular weight, can migrate through. The
size of the pores is determined by the percentage of acrylamide added to the gel. For the
second and third objectives of this study, because there wasn't a strong ERK signal
detected due to the separation of the isoforms ERK 1 and ERK 2, the percentage of
/
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acrylamide was increased to 12% to prevent this separation and mesh the ERK isoforms
together so that upon screening, a stronger signal would be detected( to create one 10ml
of 12% acrylamide resolving gel 4ml of 30% (29: 1) Bis/Acrylamide/ Acrylamide
solution, 2.5ml of 1.5 M Tris-Cl, pH 8.8, and diluted with 3.29ml of ddH20 were all
used; the volumes of of 10% SDS, 10% APS, and TEMED remain the same) Increasing
the percentage of the gel decreases the size of the pores made from the bis/acrylamide
crosslink so that the ERK 1 and ERK2 would be able to not separate upon migration
during electrophoresis. For study objective 4, the resolving gel was decreased to the
standard 10% since the issue of separating ERK isofrorms was no longer an issue and the
concentrations of those remained as previously described.
For making 4ml of 5% stacking gel solution, 2.75 ml of ddH20, O.Sml of 1.0 M Tris-Cl,
pH 6.8 Tris-base (VWR International, LLC; Cat# BDH4S00-SKGP), 0.67ml of 30%
(29:1) Bis/Acrylamide/Acrylamide solution (IBI Scientific Lot# 12Il850), 0.04ml of 10%
Ammonium persulphate or APS (VWR International; LOT# C11468) , 0.04ml of 10%
Sodium Dodecyl Sulphate or SDS solution, and 0.004ml of 99% N'N'N'N'-
Tetramethylethylenediamine for electrophoresis(TEMED) (Sigma Cat# 036K0694) were
all used.
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After twenty to thirty minutes, the ispropanolol was removed from the gel by removing
the frame from the stand, and tilting it so that the isoproterenol runs out of the fastened
glass is soaked up by the kimwipe in hand. The frame is then locked back onto the stand.
The 4ml of stacking gel solution is then poured on top of the now solidified resolving gel.
The 15 well combs are immediately inserted into the stacking gel. After twenty to thirty
minutes the stacking gel is solidified and is ready for use for electrophoresis or can be
stored by wrapping it in paper towel soaked with IX running buffer to keep the gel moist,
then wrapped in clear plastic wrap before storing it in the refrigerator.
To make lOX stock running buffer: 250mM Tris base (VWR International, LLC; Cat#
BDH4500-5KGP) 1.92M Glycine (lBI Scientific Lot # 13C3250) 1% SDS (IBI Scientific
Lot#10L3850). IX Running Buffer which is the buffer used for electrophoresis is made
by diluting the stock solution with 900ml for a final concentration of 25mM Tris base,
0.192M Glycine, and 0.1%SDS solution.
Once the gel is made, it is set up in a Bio-Rad Mini PROTEAN II cell. The IX Running
Buffer is then pored filling the chamber that contains the pre-made gel and the casket (or
another gel). Once this chamber is filled and is checked for leaks, the well comb is
removed and the lysate samples and protein marker are then loaded into their designated
well. Empty wells are filled with IX lysis buffer. Once all wells are filled, IX Running
Buffer fills the Bio-Rad Mini PROTEAN II cell and is ran for 150V for 70mins.
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2.6 Western Blot
In order to detect the presence of the phosphorylated ERK pathway, antibodies need to be
used that can target the ERK protein, Western Blotting is done. Preparation for the
transferring of the proteins from the SDS-PAGE gel to PVDF membrane involves pre-
soaking the sponges and filter papers with cold IX transfer buffer. The lOX stock transfer
buffer contain 0.25MTris base (VWR International, LLC; Cat# BDH4500-5KGP), and
1.92M Glycine (lBI Scientific Lot # 13C3250). The IX transfer buffer that is used for
the transfer is made by adding 100mi of the lOX transfer buffer and 100ml of 100%
methanol and 800ml ddH20.The PVDF membrane (Fluoro-Trans® Pall Life Sciences;
Lot# 21228A) was prepped for transfer by soaking it in 100% methanol for 5 minutes
then removed and soaked in cold IX transfer buffer. A Bio-Rad Transfer cell transfer
block was used to set up the gel, membrane, sponges and filter paper. These materials
are sandwiched together with transfer sandwich apparatus. The sandwich is set up so that
the gel is close to the anode side and the membrane is close to the cathode side. The
sponges and filter paper are used as paddening to optimize gel contact with the membrane.
The transfer was done for one hour at 100V in 4°C walk in refrigerator. Included in the
transfer apparatus was a cold ice block and stirrer to prevent overheating. Once transfer
was done, a 5% w/v blocking buffer containing Nestle® Carnation Instant Nonfat Dry
Milk, IX TBS (200mM Triza HCl, 1.37M NaCl) with 1ml of Tween 20 (VWR; Cat#
BDH4210-500ML) added to that solution (TBS plus Tween 20 also known as TBST).
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This milk solution is used to incubate the membrane. This incubation was done for two
hours at room temperature. After the blocking buffer was removed and briefly washed
with IX TBST buffer, the membrane is then incubated with primary antibody. The
primary t-ERK and p-ERK antibody solution is made at a 1:1,500 (ul/ml) dilution ofp-
ERK Mouse IgG (Santa Cruz Biotechnology Lot # L0312) and t-ERK IgG (Santa Cruz
Biotechnology Lot # F313) with 1X TBST. The membrane was incubated overnight with
the primary antibody in the 4°C walk-in refrigerator. The next day the membrane was
washed three times with 1X TBST buffer (1st time for 1 minute, 2nd time for 15 minutes,
3rd time for 10 minutes). The membrane was then incubated for two hours using
secondary antibody. The secondary antibodies used were Goat Anti mouse DyLight
650nm excitation from Thermo Scientific Lot #MC157282 (for the p-ERK) and Goat
Anti-rabbit emission DyLight 550nm from Thermo Scientific Lot# MC157244 (for t-
ERK) at 1:5,000 (ul/ml) dilution with IX TBST. After two hours, the antibodies were
removed and the membrane was washed three times with IX TBST buffer (1st time for 1
minute, 2nd time for 15 minutes, 3rd time for 10 minutes). The membrane was placed in
the black tray Alpha Innotech Imager and set on the imager on the row designated for
fluorescent imaging. The Alpha Chem FluoroChem Q program is turned on and the
image of the membrane is focused on by viewing it in "live mode" with the Epi-White
lens. Once the image of the membrane is sharp and clear, the Load Protocol menu in the
Alpha Innotech program was changed to "RG (Red-Green) blot". The "capture" button
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in the program was then pressed. The fluorescence of the secondary antibodies are
detected in order to see the concentration of total ERK and phosphorylated ERK in each
of the lystate samples.
2.7 Statistical analysis
For cAMP inhibition assay, the data analysis was done with Graph Pad Prism Software
Version 4.0 and final results exported to Microsoft Excel files stored both on the desktop
of the lab computer and in lab flash drive. The blots were quantified using Alpha Chern
Innotech Software and results were exported to Microsoft Excel files. These exported
files were then used with Graph Pad Prism Software Version 4.0 to create the final graphs
and saved on the lab desktop as well as lab flash drive.
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Chapter 3: Results
3.1 Research Objectives
This research project focused on two main aims. The first focus was to determine
whether functional selectivity could be observed when beta-blockers labetalol, alprenolol,
bucinidol, carvedilol, carazolol, propanolol, and ICI 118,551 (lCI) are bound to beta-
adrenergic 2 receptors. If functional selectivity is shown, then the second focus was to
determine if any of the beta-blockers targeted Epidermal Growth Factor Receptor (EGFR)
(a process known as EGFR transactivation) to phosphorylate Extracellular Receptor
Kinase (ERK) or if the ERK phosphorylation was solely dependent on the beta-
adrenergic 2 receptors undergoing clathrin-mediated-endocytosis (CME).
The objectives were as follows:
1. To determine how labetalol, alprenolol, carvedilol, carazolol, propanolol, bucinidol,
and leI affected the G protein dependent cyclic AMP (cAMP) pathway upon binding to
the beta-adrenergic 2 receptor.
2. To determine if the beta-blockers acting at beta-adrenergic 2 receptors can cause ERK
phosphorylation.
3. To determine if ERK phosphorylation by the beta-blockers is dependent on clathrin-
mediated endocytosis.
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4. To determine ifERK phosphorylation by the beta-blockers is linked to EGFR
transactivation.
5. To determine how blocking receptor internalization affects leI - induced ERK
phosphorylation when it binds to beta-adrenergic 2 receptors.
To assess the changes in level of phosphorylated ERK in response to beta-blocker action
at beta-adrenergic 2 receptors, antibodies specific to the phosphorylated form of ERK or
the total ERK (both phosphorylated and non-phosphorylated ERK) were used. Beta-
blockers are presumed to be solely antagonists. Detection of elevated levels of
phosphorylated ERK when these ligands are bound to the beta-adrenergic 2 receptor,
suggests that the beta-blockers are capable of agonist activity with respect to ERK.
Using Western blotting to detect changes in phosphorylated ERK, and using cAMP assay
to measure inhibition of agonist-induced cAMP accumulation helps determine if the beta-
blockers display functional selectivity by acting as antagonists with respect to the cAMP
pathway and as agonists affecting ERK phosphorylation.
EGFR transactivation involves several key proteins such as Src and EGFR. Previous
research with beta-blockers bound to beta-adrenergic 1 receptors has revealed that several
beta-blockers can activate ERK through EGFR transactivation (Kim 2008). In addition,
beta-adrenergic 2 receptors are capable of activating ERK through EGFR transactivation
(Maudsely 2000). Inhibiting the availability of Src and EGFR would help determine,
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whether the tested beta-blockers' induced ERK phosphorylation involves EGFR
transactivation. Detecting the mechanism of beta-blocker-induced ERK phosphorylation
would advance the research topic of receptor functional selectivity by bringing to light
the signal transduction pathway(s) a ligand is targeting to cause the phosphorylation of
ERK.
Human Embryonic Kidney (HEK) 293 cell line was chosen as a model to use for the
experiments because:
1. It is an easy mammalian cell line to work with and maintain
2. They endogenously express the compliment of proteins required for beta-adrenergic 2
receptor signaling as well as EGFR receptors that couple to ERK phosphorylation.
3. The cell line is easy to trans feet with plasmid vectors, which in this case was a
plasmid carrying the eDNA coding for the human beta-adrenergic 2 receptors.
3.1.2 Verification of beta-blocker activity on beta-adrenergic 2 receptors.
To investigate the first objective of determining how labetalol, alprenolol, carvedilol,
carazolol, propanolol, bucinidol, and leI affect beta-adrenergic 2 induced cAMP
accumulation, a cAMP assay was performed. HEK 293 wild type cell lines that were
transfected with beta-adrenergic 2 receptors (as described in the methods section) were
used for this experiment (for the rest of this thesis, the cell lines used will be referred to
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as HEK- ~Adr2)' Beta-adrenergic 2 receptors are coupled to stimulatory heterotrimeric G
protein Gs, which upon receptor activation, increase cAMP levels in the cell. When an
agonist binds to the receptor, an increase in cAMP accumulation occurs. If the beta-
blockers, by binding to the receptor, block the agonist from interacting with it, then the
cAMP accumulation will be reduced.
Isoproterenol, a full agonist for beta-adrenergic receptors, was the agonist used in this
assay. Figure 1 below shows the results of beta-blocker inhibition of isoproterenol-
stimulated cAMP accumulation for all the beta-blockers used in the study. From this
experiment it is evident that the presence of each beta-blocker affects the cAMP pathway
by reducing cAMP accumulation in the cell in a dose-dependent manner. This finding is
consistent with the categorization of the beta-blockers as antagonists.
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Fig. 1 Inhibition of isoproterenol-stimulated cyclic AMP accumulation by the seven beta-
blockers used in the study
3.2 Agonist and beta-blocker stimulation of HEK-pAdr2 cells increases ERK-
phosphorylation in the cells.
Unlike cAMP pathway, ERK can be activated through G protein-dependent and G
protein-independent pathways. How the beta-blockers' interactions with beta-adrenergic
2 receptors affects ERK phosphorylation was next investigated. Categorized as
antagonists, beta-blockers should reduce the amount of phosphorylated ERK in the cell.
In Figure 2 the percent change (fold change over basal) ofERK phosphorylation is
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measured for each beta-blocker and the full agonist isoproterenol. In figure 2 below, the
full agonist isoproterenol causes an increase in ERK-phosphorylation in the cell when it
binds to the receptor. However, Figure 2 also shows that all of the beta-blockers, except
lei, were capable of increasing ERK phosphorylation in the HEK-~Adr2 cells. This
finding, coupled with the results in Figure 1, suggests that the beta-blockers are not pure
antagonists but, in fact, are functionally selective for different pathways when bound to
beta-adrenergic 2 receptors. They can act as antagonists with respect to the G-protein
dependent pathway (as is evident in Figure 1 with the cAMP assay) but for ERK
phosphorylation, Figure 2 shows that they can act as partial or full agonists .
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Fig. 2 The increase levels ofERK phosphorylation when beta-blockers carvedilol (Carv), carazolol (Caraz),
propanolol(Prop), alprenolol (Alp), labetalol (Lab), bucinidol (Buc), and ICIllS,55l (ICI) and agonist is isoproterenol
(Iso) are introduced to the transfected HEK 293 cells overexpressing beta-adrenergic2 receptors. Control (CTL) is
ERK phosphorylation levels in absence of any agonists or antagonists activating beta-adrenergic 2 receptors
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The Western blots in Figure 3 provide a visual of the changes in ERK phosphorylation
levels in the cells under different conditions. The farthest left lane on each blot represents
the effect of each ligand (+Veh). The other conditions are when the beta-blocker and
isoproterenol is added along with inhibitors (0.45M sucrose, 5!lM Dynasore, 5!lM PP2,
5!lM AG1478) and the resulting change in ERK phosphorylation present in the cell. The
mechanism of action of each inhibitor will be discussed below. The two bands above
each condition (vehicle, sucrose, PP2, etc.) represents the amount of beta-blocker induced
phosphorylation of ERK (ERK 1 and ERK 2) under each condition. The darker the bands,
the more phosphorylated-ERK present in the cell.
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Figure 3: Western Blots of beta-blockers and Isoproterenol with endocytosis inhibitors (0.45M sucrose [+Suc],
Dynasore[+Dyn]) and inhibitors of the EGFR transactivation pathway (+AG1478 [for EGFR], +PP2[for Src])
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57
3.3 Blocking of clathrin-mediated endocytosis causes a reduction of beta-blocker
induced ERK-Phosphorylation
Beta-adrenergic 2 receptors can activate ERK either by using G protein switching to Gilo
protein, beta-arrestin recruitment, or EGFR transactivation (Daaka 1997, Azzi 2004,
Maudsley 2000). Common to each mechanism is that the receptor must undergo
endocytosis through a clathrin mediated process in order to phosphorylate ERK. The next
goal was to determine if ERK phosphorylation by beta-blockers is dependent on the
receptor undergoing clathrin-mediated endocytosis.
Several different clathrin-mediated endocytosis inhibitors were used to collectively to
examine the role endocytosis has on beta-blockers' ability to activate ERK. Hypertonic
sucrose (0,45M sucrose) prevents clathrin tri-skeleton from interacting with the adaptor
protein; Chlorpromazine (CPZ) is capable of removing the adaptor proteins from the
intramembrane of the cell and trapping them into microcages; and Dynasore blocks the
GTPase dynamin from budding the clathrin-coated pit containing the receptors from the
membrane and thus prevents endocytosis (Huang 2011).
L
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ERK Phosphorylation of beta-blockers with beta-
adrenergic 2 receptors in the presence of c1athrin-
mediated endocytosis inhibitors
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Fig. 4. ERK-activation of beta-blockers is dependent on endocytosis. In Figure 3A, inhibition of endocytosis of0,45M
hypertonic sucrose (Sue) and Dynasore (Dyn), significantly reduce ERK-phosphorylation levels for both agonist (Iso)
and antagonists (Carv, Caraz, Prop, Alp, Lab, and Buc), leI is an exception when it is present with sucrose. Figure 3B
shows that inhibitor Chlorpromazine (CPZ) is similar to Dynasore in that it is able to reduce ERK phosphorylation
levels for both agonist and antagonist.
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In Figure 3, the Western blots show that the presence of the endocytosis inhibitors
Dynasore (+Dyn) reduced the phosphorylated ERK in the cell for all the beta-blockers
studied in comparison to the control (Vehicle). Sucrose reduced the phosphorylated ERK
in the cells for all the beta-blockers except ICI. Figures 4A and 4B provide a quantitative
assessment of the change in ERK phosphorylation in the presence of these endocytosis
inhibitors (Figure 4A) as well as the inhibitor CPZ (Figure 4B). When inhibitors 0.45M
sucrose, 5!lM Dynasore, or 5!lM CPZ are introduced in the cells along with one of the
beta-blockers, this resulted in a decrease of beta-blocker induced ERK phosphorylated.
For instance, isoproterenol-induced ERK phosphorylation was reduced in the presence of
0.45M sucrose (Fig. 4A), Dynasore (Fig. 4A), or CPZ(Fig. 4B). Interestingly, this same
trend was seen with the beta-blockers, as illustrated in figures 4A and 4B. An exception
to this trend is with ICI in the presence of sucrose. In the presence of hypertonic sucrose,
ICI actually shows increased presence of phosphorylated ERK in the cell (Figure 3 and
Figure 4A). This finding was further investigated to better understand the relationship
between ICI and sucrose in relation to ERK phosphorylation and is discussed in section
3.4 of the thesis. In conclusion, the blots in Figure 3 and the graphs in Figure 4 show that
when the beta-blockers are bound to beta-adrenergic 2 receptors, ERK phosphorylation is
dependent on the ability of the receptor to undergo clathrin-mediated-endocytosis.
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3.3.1 Inhibition ofEGFR and Src causes decrease of beta-blocker induced ERK-
phosphorylation.
The results in Figure 4A and 4B elucidated the direct relationship between receptor
endocytosis and ERK phosphorylation when certain beta-blockers bind to the beta-
adrenergic 2 receptors. As we saw in Figures 4A and 4B, inhibiting clathrin-mediated
endocytosis by 0,45M sucrose, Dynasore, or CPZ affected the beta-blocker induced ERK
phosphorylation. These results corroborate the idea that beta-blockers could be activating
ERK through one of the three pathways (G protein switching to Gi/o protein, beta-arrestin
mediation, or EGFR transactivation) since each process is dependent on clathrin-
mediated endocytosis.
To determine if one of these pathways, EGFR transactivation, is linked to beta-blocker
induced ERK phosphorylation, inhibitors of EGFR and Src were used. Endogenous
EGFR and Src are present in the HEK- PAdr2 cells making investigation of this pathway
possible. To study the effect ofEGFR transactivation on beta-blocker-induced ERK
phosphorylation, the inhibitor PP2 was used to inhibit Src activity and the inhibitor
AG1478 was used to inhibit EGFR activity. PP2 works by binding to Src in its ATP
binding domain, which prevents its activity (Li 2006). AG 1478, is a potent inhibitor of
EGFR, and when it binds to the receptor, its high affinity prevents dissociation of the
compound from the receptor and makes the EGFR inactive (Li 2006).
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As the graph Figure 5 below shows, the inhibition ofEGFR by AG1478 and the
inhibition of Src by PP2 results in a reduction of the ERK phosphorylation for the agonist
isoproterenol.
ERK Phosphorylation of Beta-blockers with Beta-
Adrenergic 2 receptors Exposed to EGFR inhibitors
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Fig. 5. ERK Phosphorylation of beta-blockers is dependent on the presence ofEGFR and Src. Using the inhibitors of
Src activity (PP2) and EGFR activity (AG I478) ERK phosphorylation induced by beta-blockers and by agonist
isoproterenol is significantly reduced.
The Western blots in Figure 3 also provide a visual of these inhibitors' effect on ERK
phosphorylation levels in the cell. Specifically, in the presence of inhibitors AG 1478 or
PP2, there are less phosphorylated ERK present in the cells in comparison to control. It is
also evident from the graph in Figure 5 above that, for all the beta-blockers, the inhibition
of EGFR by AG 1478 resulted in lowest amount of ERK phosphorylation. The data
suggests that the beta-blocker-induced ERK phosphorylation observed involves EGFR
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transactivation. This finding is interesting since the full agonist isoproterenol shares the
same dependency on EGFR and Src for ERK phosphorylation, supporting the idea that
the beta-blockers studied can display agonist-like characteristics for certain pathways.
Collectively, the cAMP accumulation assay and the Western blot experiments suggest
that the beta-blockers studied, when bound to beta-adrenergic 2 receptors, are
functionally selective and act as antagonists for cAMP accumulation while for the ERK
phosphorylation, show partial-or full-agonists characteristics (except for ICI). Comparing
the graphs in Figures 4A and B which shows the effect of the c1athrin-mediated
endocytosis inhibitors had on beta-blocker induced ERK-phosphorylation with Figure 5
which shows the effect of the EGFR inhibitor and Src inhibitor on beta-blocker induced
ERK-phosphorylation, also suggest that these selected beta-blockers are dependent on
EGFR transactivation to phosphorylate ERK. Clathrin-mediated endocytosis also affects
these beta-blockers' ability to phosphorylate ERK, however, not to the same degree as
EGFR or Src inhibition.
With the beta-blocker ICI, a surprising increase in ERK phosphorylation was observed in
the presence of 0.45M sucrose (Figure 3 and Figure 4A). This is surprising because, as a
highly selective beta-adrenergic 2 antagonist, ICI is expected to not produce an increase
in ERK phosphorylation under any experimental condition. The observation with ICI and
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0.45M sucrose led to further scrutiny of how receptor internalization can contribute to the
mechanism of leI-induced ERK phosphorylation.
3.4 Investigation into I'Cl, Sucrose, and ERK Phosphorylation gives inconclusive
results
The objective of this research project was to determine 1) whether presence oflel will
reduce isoproterenol-induced ERK phosphorylation levels, and thus confirms its
antagonist characteristic, and 2) whether the leI-induced increase in ERK-
phosphorylation observed in Figures 3 and 4A is due to inhibition of receptor
internalization by sucrose.
Unfortunately, the data generated for this research is currently inconclusive in answering
these two questions due to issues with Western Blotting and more work will need to be
done. This experiment should have shown that when administered to HEK 293-PAdr2
cells, isoproterenol would increase phosphorylation of ERK. But when both leI and
isoproterenol were present, the ERK phosphorylation levels would be reduced because
leI would block isoproterenol from binding with the beta-adrenergic 2 receptors.
Observing this result would verify leI's ability to behave as an antagonist of the ERK
pathway for beta-adrenergic 2 receptors. The 0.45M sucrose with and without leI would
help piece together whether K'I's mechanism is affected by the presence of hypertonic
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sucrose. This experiment would help determine if the presence of 0.45M sucrose can
cause ICI to increase the level of phosphorylated ERK.
The rest of this chapter will show the current data gathered from the work addressing if
sucrose can affect ICI-induced ERK phosphorylation. An analysis of each experiment's
short comings as well as what improvements should be made for the future will also be
discussed. The experiments were repeated multiple times using two clonal cell lines of
HEK 293-~Adr2 cells (CLAI and #2). Two clones of the same cell line were used to
prevent potential system bias that could affect the interpretation of the results. For
instance, CLAI HEK- ~Adr2 cell clone (CLAI) has a higher density of beta-adrenergic 2
receptors than the #2 HEK- ~Adr2 cell clone (#2). On the PDVF membranes used in
Western blotting, the intensity of the immunoreactivity ofERK phosphorylation (as
shown in Figures 6-8 below) from samples generated using #2 clone are lower in
intensity than samples of the CLAI clone. The CLAI clone has a higher number of beta-
adrenergic receptors in comparison to the #2 clone. This results in a higher amount of
ERK phosphorylation in the cell for the CLAI clone. Using both cell clones provide the
assurance that the change in ERK phosphorylation shown in the blot is truly due to the
activity of the ligand at the receptor, not the cell line used.
The intensity of each band in the blots below in Figure 6 represents the amount of
phosphorylated ERK in the cell under each experimental condition (for this experiment
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the variables are isoproterenol, ICI, sucrose, or combination of two of the variables). The
darker and bolder the band from the samples, the more phosphorylated ERK present in
the cells.
Figure 6 shows the Western Blot of the first experimental trial with isoproterenol, ICI,
and sucrose (Set#l)
B
Figure 6: Western Blot of both phosphorylated ERK (p-ERK) and total-ERK (t-ERK) of ICI, 0.45M Sucrose (Sue),
and isoproterenol (Iso) experiment. This is the first set of data for this experiment. The first six lanes is the experiment
run with the CLAI clone, and lanes7-12 are the experiment run with the #2 clone. Figure 6A is the blot displaying p-
ERK in the samples and Figure 6B is the blot displaying t-ERK in the samples
Looking at the ERK phosphorylation (p-ERK) blot in Figure 6A. it shows that there is a
reduction of phosphorylated ERK in the first control lane (lane #1) in comparison to lane
66
labeled isoproterenol (lane#2). As discussed in the methods section, the goal of serum
starvation is to reduce the level of ERK in the cells to their most basal levels. The
controls in lanes 1,4, 7, and 10 are the basal levels of phosphorylated ERK in the cell
before any drug or inhibitor is added. Having this lane is important in determining how
the addition of the drugs or sucrose changed the levels of phosphorylated ERK in the
cells. As shown in Figure 6A, in comparison to the control, the addition of isoproterenol
increases ERK phosphorylation in the cell. Furthermore, in comparison to the ERK
phosphorylation levels in lane 1, the lane labeled sucrose and ICI (ICI+Suc, lane 6), has a
higher ERK phosphorylation level. This indicates that ICI and sucrose together increase
the amount ofERK phosphorylation in the cell. However, comparing lane 6 to the lane
with Sucrose alone (lane 5) it seems that the lanes have similar ERK phosphorylation
levels. This indicates that the addition of ICI may not significantly change the amount of
ERK phosphorylation in the cell. Looking at the #2 cell clone samples in Figure 6A, the
relationship between isoprotemenol alone and with ICI is similar to what is seen in the
CLAI samples. However, when observing the samples from the #2 cell clone, it appears
that sucrose doesn't increase phosphorylated-ERK levels in the cell nor does sucrose with
ICI. It is the conflicting results seen in Figure 6 that required repeats of this experiment
to try to understand the relationships of ICI, sucrose, and ERK-phosphorylation.
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Collectively the p-ERK blot in Figure 6 shows that isoproterenol increases
phosphorylated ERK, however when ICI and isoproterenol are both introduced to the
cells, the amount of ERK phosphorylation in the cells is reduced. It can be inferred that
ICI is capable of blocking isoproterenol's (an agonist) ability to bind to beta-adrenergic 2
receptors and, subsequently, increase ERK phosphorylation levels in the cell. However
based on the same figure, it is questionable if when 0.45M sucrose is introduced to the
cells, there is an increase in ERK. Similarly, when ICI is present with the sucrose, it is
questionable its role in ERK-phosphorylation. ICI is unable to significantly reduce the
sucrose-induced phosphorylated ERK levels like it did when for isoproterenol. This
means that ICI does not playa significant role on 0,45M sucrose-induced ERK
phosphorylation levels. When analyzing results of West em-blots, it is important to ensure
that the variation in ERK phosphorylation observed is due solely to the experimental
variables introduced. Monitoring the level of total ERK (t-ERK) helps prevent
misinterpretation of changes in phosphorylated ERK levels. As long as each sample
shows relatively the equal amount oft-ERK, this confirms that the p-ERK levels shown
are due to the experimental variables and not unequal volumes of protein sample loaded
onto the SDS PAGE gel. For this reason the amount of phosphorylated ERK is
normalized relative to the total ERK in each sample.
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For instance, looking at the CLAI samples in the two lanes labeled control (lanes 1 and 4)
in Figure 6A, there is a significant difference in ERK-phosphorylation levels between the
two, even though they were measured under the same experimental condition. This is a
sign that there may be a problem with how the samples were loaded onto the gel and that
the interpretation of the p-ERK blot may not be accurate. To confirm if human error is
the cause to the different ERK-phosphorylation levels between lanes 1 and 4, the total
ERK levels for these two lanes, seen in Figure 6B, are observed. Observing the total ERK
(t-ERK) of all samples is ideal because as long as the same cell line is used to conduct the
experiment, the total ERK observed within each sample should be relatively the same
with little, if any, variation in concentration.
Looking at the t-ERK levels for CLAI samples in Figure 6B, the second control (lane 4)
lane has a much higher level oft-ERK than the first control (lane 1) indicating that there
was more protein of the second control sample loaded into its well than the first control.
This also explains the p-ERK differences between the two CTL samples seen in Figure
6A since having more protein in the sample in the well would result in more
phosphorylated ERK being detected by the antibodies. Because the second control lane
has similar t-ERK levels as the other lysate samples, it appears that too little lysate
sample of the first control was added. To correct this error, better precision when
dispensing volumes of lysate samples into wells when using the pipet is necessary.
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Specifically, care should be taken so that after turning the dials on the pipet to the desired
volume, the pipet tip is completely filled with the lysate sample before removing it from
the vessel containing the lysates. Again, proper pipet handling would prevent this error
from occurring.
Looking at Figure 6A, a similar situation occurred in the lanes with the CTL samples
(lanes 7 and 10) from the #2 cell colony. Looking at Figure 6B, the #2 sample set, the
second control lane (lane 10) appears to have more lysate sample in comparison to the
other samples. It appears that too much of the sample was added to the wells and that's
why a higher p-ERK is observed in that lane in comparison to the first control lane.
Specifically, better pipet handling would help prevent this error. Because it is difficult to
assess the precision of loading equal volumes of samples into a gel until the blotting
procedure is done, this error could not be corrected nor detected until the final step of the
procedure.
Figure 7 below is an example of the ideal appearance ofa Western Blot when each step is
properly followed. For both CLAI and #2 samples, there is a reduction of isoproterenol-
stimulated ERK activity when ICI is introduced. Although this is clearly visible with the
CLAI samples, it is less apparent with the #2 samples in the figure.
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Figure 7: Western Blot of both phosphorylated ERK (p-ERK) and total-ERK (t-ERK) of ICI, 0.45M Sucrose (Sue),
and isoproterenol (Iso) experiment. This is the second set of data for this experiment. The first six lanes is the second
experiment run with the CLAI clone, and lanes 7-12 are the experiment run with the #2 clone. Figure 7A is the blot
displaying p-ERK in the samples and Figure 7B is the blot displaying t-ERK in the samples
This is because, as discussed previously, the #2 cell clone of HEK- ~Adr2 cells have a
slower growth rate than CLAI HEK- ~Adr2 cells. Since the cells were grown for the same
amount of time before using them for experiment, the CLAI HEK- ~Adr2 cell clone has
the higher density of cells than #2. As a result of this, when the samples from the CLAI
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cell clone and #2 cell clone are ran together, more antibodies will bind to the total ERK
and phosphorylated ERK in present in the CLAI's samples than in the #2 samples.
To improve #2 samples' blot intensity and detection, the #2 samples were ran on
different gels than the CLAI samples so that detection wouldn't be influenced by the
higher intensity of samples taken from the CLAI clone. To conserve materials, two
experiments were done with both cloned lines before Western blotting. Set #3 was done
one week before Set #4. The sample sets from each experiment were ran together.
Because of this, Figure 8A & 8B shows the results from two experiments(Set #3 and Set
#4) for each clone line, Set #3 and Set#4 using CLAI and Set#3 and Set#4 from clone cell
line#2.
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Fig. 8 Western Blot of both phosphorylated ERK (p-ERK) and total-ERK (t-ERK) of ICI, 0.45M Sucrose (Sue), and
isoproterenol (Iso) experiment. This is the third and fourth sets of data for this experiment. Figure 8A is the blot
displaying p-ERK and t-ERK of CLAI samples. The first six lanes are from the fourth experiment run with the CLAI
clone, and lanes 7-12 are from the third experiment run with the CLAI clone. Figure 8B is the blot displaying p-ERK
and t-ERK in the samples of the #2 clone. The first six lanes are from the third experiment run with the #2clone, and
lanes 7-12 are from the fourth experiment run with the #2 clone.
Figure 8A demonstrates how salt content from the media that hasn't been fully removed
from wells during drug stimulation can affect how sample migrate on gel as well as
improper sample preparation during the lysis stage of drug stimulation can affect sample
migration.
Electrophoresis can be drastically affected by unequal loading of sample in each well (as
demonstrated by Figure 6), or due to excess salt in lysate. Both cases result in uneven
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electric current across the field and lead to irregular migration pattern of the samples.
Figure 8A clearly shows this, specifically lanes 1-6 suggests that it is not the differences
in lysate sample volume but differences in salt concentration of the samples that are cause
of the irregularity in migration. A possible reason for the appearance of Set#4 samples in
Figure 8A is due to few if any cells left in the cell plates by the time the samples were
collected at the last step of drug stimulation. Looking at the t-ERK blot in Figure 8A
there is very little detection oft-ERK which questions whether sufficient amount of cells
were collected during cell lysis phase of the experiment.
How this may have happened is that on the day the experiment was conducted, several
errors occurred. The first irregularity was that during washing of the cells with media to
remove serum from the cells, the cells were not characteristically adherent to the plate. A
lack of adhesion may have been due to too dilute of the poly-lysine solution. Poly-lysine
solution is used as a coating for the cell plates to help improve adhesion of cells to the
cell plate. Because lysine is a positively charged amino acid, coating the plates with the
poly-lysine solution takes advantage of the fact that the cell-membrane is negatively
charged due to phosphate-group of the phospholipids that the cell membrane is made up
of so theoretically the cells will adhere to the plate more efficiently due to the ionic bond
between the lysine and cell membrane. In the case of Set#4, since a significant amount of
cells were lost during the washes, possibly too dilute of poly-lysine solution used to coat
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the tissue culture plates. However, it is uncertain if the poly-lysine concentration is the
true reason for lack of cell adhesion. The uncertainty is because the fourth trial (Set #4)
was the last trial ran. However, based on what was observed, this possibility seems to be
the most reasonable. Despite the observation of cells not attaching well onto the plate, the
experiment was continued because instead of typically using the 24-well plate to do the
experiment, a 12-well plate was used which has a larger surface area. The belief was that
despite the cell loss, since more cells were in the wells to begin with (in comparison to
the 24 well plate), the cells left in the 12-well plate would be enough to continue with the
experiment and ERK-phosphorylation levels would still be detected. A major error in this
rationale is that if poly-lysine concentration is the issue, then regardless of the surface
area, the lack of adhesion of the cells to the plate would affect the drug-stimulation and
cell lysis. In addition although cells were detected in the wells immediately after the wash
phase of the serum starvation, they were not re-examined before continuing with the
drug-stimulation phase of the experiment, because an assumption was made that
incubation should not change cell adhesion. This assumption did not take into
consideration cell loss that would be detectable after the cells were washed. As the t-ERK
blot in Figure 8A shows very little t-ERK present, it is questionable if the lysate collected
after this experiment, had enough cells to even determine the presence oft-ERK or p-
ERK.
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In future experiments, more care will be taken to check the state of the cells before
proceeding to any other process in the experiment. The issue with cell adhesion should
also be fully addressed before doing drug-stimulation to ensure that a sufficient number
of cells were attached. Although the cells were checked for adhesion before leaving the
plate in the 37°C incubator for the six-hours, they were not checked before the serum
starvation based on the assumption that the cells observed would stay alive after the
incubation.
The non-uniform migration of the samples on the gel stems from unequal salt
concentration from the each sample. How this may have occurred is that during the 80°C
or the 9SoC heating stages of sample preparation, some of the lysis buffer may have
evaporated leaving excess salt in the samples. Not taking this into consideration risks
making the samples to migrate irregularly due to the fact that the excess salt affected the
electrical current as it ran through the gel. Care should be taken to prevent samples from
having high salt content because it affects the uniformity of the current through the gel
and in addition can lead to skewed bands as is very clearly seen in set #4 of Figure 8A.
Excess salt concentration could have also came from drug stimulation phase of the
procedure, when the media was removed from the plate. The media wasn't removed from
the wells as vigorously as in past experiment trials for fear of losing more cells. Doing
this increased the possibility of remnant media (which contains salt) in the wells which
would explain the irregular migration of Set#4. In contrast to Set#4, set #3 samples (also
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in Figure 8A and 8B) were collected, a week before set#4. The errors discussed with
Set#4's samples were not observed with the Set #3. However, because Set#3 and Set #4
were ran together, the excess salt concentration from the Set#4 samples, affected the
migration of the Set#3 samples. Once again, to correct for this error, if an observation of
significant cell loss is observed, then the experiment should be discontinued no matter
what the plate size is since regardless of plate size. In, addition, proper care should be
taken to make sure that samples are covered during the 80°C and 9SoC heating steps so
that buffer doesn't evaporate.
Looking at Figure 8B, it appears that Set #4 of the #2 clone also has the same issue with
low t-ERK and p-ERK concentrations, however not as significant as Set#4 of the CLAI
samples. Particularly in Figure 8B, Set#4's Sue and ICI+Suc samples show irregular
migration and very low t-ERK and p-ERK levels. Because the migration of those two
samples is not the same as the migration of the other samples and the migration of those
samples look similar to the migration of Set#4 of the CLAI samples in Figure 8A, it is
probable that there was excess salt concentration from the media in those two samples
(Sue and the ICI+Suc samples of Set#4, of the #2 cells) and that is what accounts for their
appearance in Figure 8B. However, because it only occurred in those two samples, it is
questionable if this is the case. Another, more likely explanation could be that
insignificant amount of sample was loaded into those wells. More specifically, those two
samples probably spilled out of the wells while they were being loaded.
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Based on all the blots, both cell clones show that the antagonist ICI reduces
isoproterenol- induced ERK phosphorylation. However, how well ICI is able to reduce
isoproterenol- induced phosphorylation is questionable. Although it appears that sucrose
is increasing ERK phosphorylation in the cell, how significant the increase is, still needs
further investigation. Lastly, with both clones (CLAI and #2) ICI appears to reduce
sucrose-induced ERK phosphorylation, not increase the amount ofERK-phosphorylation
present as Figure 3 showed earlier.
The major error with this experiment was the lack of consistency in data. Further
experimentation would be needed in order to determine how sucrose is affecting ERK
phosphorylation levels and also how ICI affects the sucrose-induced ERK
phosphorylation levels.
Chapter 4: Discussion
4.1 Overview of Results
Functional selectivity is the ability of a drug, through the interaction with its target
receptor, to selectively influence the inhibition or activation of different signaling
pathways coupled to that receptor. When bound to beta-adrenergic 1 receptors, beta-
blockers have been found to inhibit the cAMP pathway while simultaneously increasing
the levels of ERK phosphorylation. The concept of functional selectivity is in contrast to
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the theory of two-state receptor model, which views the receptor as existing in two
potential conformations, activate or inactive. Under this theory, beta-blockers are
believed to only favor the receptor's inhibition conformation (Patel 2010). However, the
observation of functional selectivity suggests that receptors can exist in multiple active
and inactive conformations.
This project focused on three main aims. The first objective was to verify that the beta-
blockers labetalol, alprenolol, bucindolol, carvedilol, carazolol, propanolol, and leI
118,551 behave as antagonists with respect to beta-adrenergic 2 receptor-stimulated
cAMP accumulation, but behave as agonist with respect to ERK phosphorylation by the
same receptor. This characteristic is known as functional selectivity. If functional
selectivity is verified, then the second objective was to focus on the ERK phosphorylation
and determine if ERK phosphorylation is dependent on clathrin-mediate endocytosis.
Because previous research with beta-blockers has shown that ERK-phosphorylation can
occur through EGFR transactivation (a process dependent on clathrin-mediated
endocytosis).The second objective was extended to determine if the beta-blocker-induced
ERK phosphorylation was dependent on EGFR and Src, key proteins in EGFR
transactivation process.
The data from this research project shows that these beta-blockers display functional
selectivity when bound to beta-adrenergic 2 receptors in a manner similar to what has
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been observed with beta-adrenergic 1 receptors. When measuring cAMP accumulation (a
product of G-protein activation), the beta-blockers were antagonistic and were able to
reduce the agonist-stimulated cAMP accumulation in the cells as expected. However,
when observing ERK phosphorylation, the beta-blockers did not reduce ERK
phosphorylation but instead directly increased ERK phosphorylation. The results
presented here add to the research which supports the idea that certain beta-blockers are
capable of functional selectivity at beta-adrenergic 2 receptors.
The second objective was to determine if the induced ERK phosphorylation was
dependent on clathrin-mediated endocytosis. From this study, the results showed that
beta-blockers in the presence of clathrin-mediated endocytosis inhibitors 0.45M sucrose,
CPZ, and Dynasore had a lower amount of ERK phosphorylation present in the cells
when endocytosis was inhibited. This finding was important because the three processes
by which beta-adrenergic 2 receptors can cause ERK phosphorylation (G protein
switching to GilD protein, beta-arrestin activation, EGFR transactivation) are all dependent
on clathrin-mediated endocytosis. Itwas also important for us to use different inhibitor
agents to remove experimental setup bias as a possible reason for the changes in ERK
phosphorylation amount in the cell. 0.45M sucrose is capable of inhibiting clathrin
assembly from interacting with the adaptor protein. Chlorpromazine (CPZ) inhibits the
adaptor proteins from the intramembrane and traps them into microcages; doing so
prevents endocytosis; Dynasore blocks the GTPase dynamin from budding the clathrin-
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coated pit containing the receptors from the membrane to the intracellular and thus
prevents endocytosis.
The third objective was to determine ifEGFR transactivation by beta-adrenergic 2
receptors is necessary for beta-blocker-induced ERK phosphorylation. When EGFR and
Src were inhibited, ERK phosphorylation was significantly reduced by all of the beta-
blockers studied. This implies that the beta-blockers used in this experiment are highly
dependent on the presence ofEGFR and Src for ERK phosphorylation.
What's surprising about these findings is the uniformity in mechanism of action of all the
studied beta- induce ERK phosphorylation. This is especially interesting because no past
research has shown a collection often beta-blockers having a uniform dependency on the
same pathway for ERK phosphorylation. For instance, a 2008 study showed that out of a
collection of beta-blockers screened which included labetalol, bucindolol, carvedilol,
propanolol, and alprenolol; only alprenolol and carvedilol were able to stimulate ERK
through EGFR transactivation (Kim 2008). Another study focused on beta-blockers
bucindolol and propanolol with beta-adrenergic 1 receptors. The experiment conducted in
this study used inhibitors of G i/o (pertussis toxin), G, (cholera toxin) and Src (PP2) to
determine the dependence of these beta-blockers on these proteins to phosphorylate ERK.
The researchers found isoproterenol can phosphorylate ERK using either G i/o, G, , or Src,
but the presence of Src was important for propanolol and bucindolol's induced ERK
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phosphorylation (Galandrin 2008). It is interesting that previous research has shown
various ways that beta-blockers can increase levels ofERK phosphorylation when
binding beta-adrenergic 1 receptors, yet this research doesn't show this variation in
mechanism when the same ligands bind to beta-adrenergic 2 receptors (Azzi 2002, Kim
2008).
As discussed in the introduction, beta-arrestins playa role in EGFR transactivation by
recruiting Src. Src then activates EGFR and the receptor initiates the MAPK kinase
pathway and as a result of this activation ERK becomes phosphorylated. So indirectly,
EGFR transactivation by GPCRs is dependent on beta-arrestin (Kim 2008,Noma 2007).
In future research, beta-arrestin 1 and 2 should be knocked out to determine if they playa
significant role in beta-blocker induced ERK phosphorylation. Performing this
experiment with the drugs propanolol, ICI, and carvedilol would be of great interest. A
2002 study investigating propanolol and ICI found that the inverse agonists are all
capable of recruiting beta-arrestin 2 for ERK phosphorylation. Carvedilol was also found
to recruit beta-arrestin in a 2007 study (Wisler 2007).
From the results presented, it cannot conclude with certainty that functional selectivity at
beta-adrenergic 2 receptors was observed. The HEK 293 cells line used in this study
could express endogenous alpha-adrenergic receptors and beta-adrenergic 1 receptors
since Because most of the beta-blockers used in this experiment are either non-selective
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for both receptors or more selective for beta-adrenergic 1 receptor than beta-adrenergic 2
receptor, care should have been taken to ensure that the increase in ERK phosphorylation
levels is due solely to the drug's interaction with beta-adrenergic 2 receptors and not the
possible beta-adrenergic 1 or alpha adrenergic receptors that may be present in the cells.
To confirm that these drugs' functional selectivity at beta-adrenergic 2 receptors, an
inhibitor for beta-adrenergic 1 (CGP-20712A), beta-adrenergic 2 (ICI), alpha-adrenergic
1 receptors (prazosin) and alpha-adrenergic 2 receptors (rauwolscine) should be used in
the presence of the beta-blockers. If the ERK phosphorylation increase is primarily due to
the drug's interaction with beta-adrenergic 2 receptors, then in the presence ofICI (which
is highly selective for beta-adrenergic 2 receptors), there should be a significant reduction
of phosphorylated ERK in the cell. Also, in comparison to the presence of the other
inhibitors, the reduction of phosphorylated ERK should be the lowest in the presence of
ICI. For alprenolol, doing this experiment is important because previous has found that
alprenolol-induced ERK phosphorylation levels were dependent on the presence of both
alpha and beta-adrenergic receptors (van der Westhuizen 2014). This means that the ERK
phosphorylation induced by alprenolol was not fully due to its interaction of beta-
adrenergic 2 receptors making deciphering its functional selectivity with the receptor
difficult.
The same research group that studied alprendolol, also screened beta-blockers labetalol,
bucindolol, propanolol, and carvedilol's ERK phosphorylation. This research group
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found that those beta-blockers' induced ERK phosphorylation were primarily dependent
on the presence of beta-adrenergic 2 receptors. The ERK phosphorylation levels seen in
our cells are likely from ligand interaction with beta-adrenergic 2 receptors alone.
Carazolol, was not screened in that research study, so for now it is unknown if the ERK
phosphorylation observed with carazolol is due solely to its interaction with beta-
adrenergic 2 receptors.
A way we can confirm all of this is to use an experimental setup with each beta-blocker
with and without the addition of ICI. Theoretically, if a beta-blocker' s induced ERK
phosphorylation is primarily due to the drug's interaction with the beta-adrenergic 2
receptor; then when the beta-blocker and ICI are both present in the cells, the ERK
phosphorylation should be lower when the beta-blocker is present in the cells alone.
The fourth goal of this research was to determine the relationship between ICI, sucrose,
and ERK phosphorylation. When ICI along with other beta-blockers were investigated to
detect changes in ERK phosphorylation levels in the presence of clathrin-mediated
endocytosis inhibitors CPZ, Sucrose, and Dynamin, all beta-blockers, except ICI, showed
a decrease in ERK phosphorylation. ICI in the presence of inhibitor Dynamin and CPZ
showed no significant change in ERK phosphorylation levels, however in the presence of
sucrose there was an unusual increase in ERK phosphorylation levels. This observation
gave the impression that ICI was capable of inducing ERK phosphorylation in the
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presence of sucrose by a mechanism that was not dependent on clathrin-mediated
endocytosis. Although one study showed that ICI can increase phosphorylate ERK in the
cells by recruiting beta-arrestin, the fact that beta-arrestin mediated ERK phosphorylation
is dependent on endocytosis questioned whether this idea is applicable to the observation
seen in this research (Azzi 2004).
Inconsistent data, potentially the results of "human errors" made in process of
conducting experiments (as illustrated in Figures 6-9) prevented the assessment of the
effects of sucrose on ICI-induced ERK phosphorylation. In the future, more care in
administering each step of the experimental setups (serum starvation, drug stimulation,
and SDS-PAGE, and immunoblotting) will be followed so that better analysis of the
results can be done. Since most of these mistakes cannot be detected until the last step of
the Western Blot procedure, it was not possible to correct them beforehand.
4.2 Future Study
Although this study showed that EGFR transactivation is heavily involved in the ability
of beta-blockers to induce ERK phosphorylation, the role of beta-arrest ins was not
investigated. By knocking out beta-arrestin 2 in the cells and comparing the
phosphorylated ERK levels under this condition in comparison to control conditions
(unaltered expression of beta-arrest ins) would provide insight into the role of beta-
arrestin in mediating beta-blocker-induced ERK phosphorylation. If these drugs showed
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to be dependent on beta-arrestin, further investigation could focus on the extent to which
each beta-blocker is dependent beta-arrestin recruitment. Investigation of this will
provide more detailed understanding of these beta-blockers' mechanism of action and
possibly provide a linkage between their mechanism of action and their clinical affect.
A second research study could be on the role of lipid roles for each beta-blocker's ERK-
phosphorylation induction. As discussed in chapter one, lipid rafts appear to be important
for beta-adrenergic 2 receptor G-protein switching and can only be formed in the absence
ofbeta-arrrestin (Ostrom 2004). If, by using MBCD (an inhibitor of lipid raft
congregation), ERK- phosphorylation levels induced by a beta-blocker are reduced, then
this could potentially show that lipid rafts have a role in promoting ERK phosphorylation
as well as the role of G-protein switching would have for the beta-blocker's induced ERK
phosphorylation.
Another research project could be taking the results of this study and quantifying them
using an equation similar to the one below.
Alog (..._!_). = log (_!_) . - log (~).
KA KA LIGAND KA· ISO
This equation looks at a ligand's (beta-blocker's) change in ratio between ligand-receptor
coupling efficacy for a pathway (r) and ligand affinity for receptor (Ka). This is
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determined by the difference between the ratio of ligand-receptor efficacy to ligand
affinity for the beta-blocker 10""(":".) '.'''AN..•and the ratio of ligand-receptor efficacy to
ligand affinity for isoproterenol 'Og(i~) ISO.
The difference "-.Og(k':J, is the quantification of the ligand bias of the beta-blocker for
activating a pathway. This number allows researchers to compare different ligands based
on their activation abilities for different pathways.
Future research could use a formula similar to the one above to determine how dependent
a ligand is on a process to cause ERK phosphorylation .. Because beta-adrenergic 2
receptors are capable of increasing ERK phosphorylation levels either through G protein
process (O-protein switch from Os to Gi/o), beta-arrestin, or EGFR transactivation (Daaka
1997, Kim 2008); this would be of great interest to researchers. As discussed in chapter
one, beta-blockers when bound to beta-adrenergic 1 were diverse in how they activated
ERK (Galandrin 2006, Kim 2008), determining pathway selectivity for ERK activation
by these beta-blockers could be another step further in understanding the underlining
mechanism of how these beta-blockers work on a molecular level.
The connection of what pathway is being activated by a beta-blocker and the beta-
blocker's success in treating a disease could be important because of the research looking
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into the clinical consequences of pathway activation. For instance, one important research
showed the connection between ERK activity and myocardial infarction. The research
team used the heart tissue of pigs pre-conditions for ischemia to determine the
importance of ERK and EGFR activation. The researchers found that inhibiting EGFR
and ERK resulted in myocardial infarction confirming that the presence of both EGFR
and ERK were important for preventing cardiac damage due to ischemia (Strohm 2000).
Another research group found that beta-adrenergic 1 receptor's EGFR transactivation was
important in reversing apoptosis in tissue from patients with chronic heart failure (Noma
2007). These observations connect beta-adrenergic activity, EGFR transactivation by
these receptors ERK activity, and clinical outcomes. This connection shows the
importance investigating functional selectivity of ligands able to activate ERK through
beta-adrenergic receptors (such as beta-blockers) from pharmacological and clinical
standpoints (van der Westhulzen 2014). Understanding what pathways these beta-
blockers can use to cause ERK phosphorylation can provide a more clear understanding
of how these beta-blockers are effective in treating cardiovascular diseases.
A comprehensive understanding of the underlining function selectivity each beta-
blockers would be of great interest in the field ofbioinformatics. Specifically, this
additional information could be used to develop algorithms that would be able to
accurately predict which beta-blockers would be ideal candidates for certain
cardiovascular diseases or other diseases. A 2010 study led by Dr. Chen created a
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framework designed to incorporated curated data on drug activity, protein activity, and
the disease of interest then, using algorithms, analyze each drug's pathological make-up
to determine which of the drugs make strong candidates for treatment for a disease
(Huang 2011). The last possible future study could involve a bioinfomratic analysis of the
pathways beta-blockers target incorporating the new data on each beta-blockers'
functional selectivity. The algorithms used by Dr. Chen's lab could then be used to
determine drug candidates for different diseases. Usually webpages are made to display
the complex pathological networks of these drugs to proteins, however, having a table
like the one below would allow researchers' findings of each beta-blocker's functional
selectivity to be comprehendible to not only themselves, but also to the general public
who may be interested in viewing this information.
Table 1: Possible organization of information related to functional selectivity of
beta-blockers and isoproterenol with beta-adrenergic 1 and beta-adrenergic 2
receptors.
Beta-Adrenergic 1 receptors Beta-Adrenergic 2 receptors
Name of Ligand cAMP ERK Internalization ERK
Internalization
pArrs EGFR G vO CME CIE pArrs EGFR Gvo CME CIE
trans lR other trans lR other
labetolol
Alprenolol
Bucinidol
Carvedllol
Carazolol
Propanolol
ICI
Isoproterenol
CME= clathrin mediated endocytosis
CIE=clathrin Independent endocytosis
lR= lipid rafts
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From the table, a researcher would at once have complete knowledge about each beta-
blockers' effect on cAMP accumulation, ERK phosphorylation, and internalization when
interacting with beta-adrenergic 1 and beta-adrenergic 2 receptors. Because beta-
adrenergic 3 receptors are not as prominently expressed in the body, except in adipose
tissue, and are not a primary target for these beta-blockers, they weren't included in this
table. From previous research it appears that the mechanism of action for a beta-blocker-
induced ERK phosphorylation may be dependent on the beta-adrenergic receptor it is
bound to. An example of this is when labetalol is bound to beta-adrenergic 1, there
appears to be no EGFR transactivation occurring; whereas in this study when labetalol
was bound to beta-adrenergic 2 receptor, its ERK-phosphorylation induction was
dependent on EGFR transactivation. To account for this, the table above has a section for
beta-adrenergic 1 related actions (ERK phosphorylation and Internalization) and beta-
adrenergic 2 related actions. As discussed in chapter one, there are various ways of
activating each pathway which this table also takes into consideration. The three
pathways that are known to induce ERK phosphorylation (beta-arrestins (~Arrs), EGFR
transactivation (EGFR trans.) and G-protein switching to G i/o (Gi/o) are under the ERK
heading in the table, and the processes known to lead to endocytosis (clathrin mediated
endocytosis (CME) and clathrin independent endocytosis (CIE) would be under the
internalization heading. Under the clathrin independent heading, is the lipid rafts (LR)
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and other, for other processes of clathrin independent endocytosis (such as dynamin
independent endocytosis).
4.3 Conclusion
In conclusion, the study found beta-adrenergic blockers labetalol, alprenolol, bucindolol,
carvedilol, carazolol, ICI 118, 551 and propanolol display functional selective activity at
beta-adrenergic 2 receptors. Specifically, these beta blockers when bound to the receptor
have an inhibitory affect on cAMP accumulation while simultaneously increasing the
presence of phosphorylated ERK. In addition, these beta-blockers used in the study were
all dependent on EGFR and Src (to a lesser degree) for their induced ERK
phosphorylation. These findings suggest that the source of ERK phosphorylation by these
beta-blockers is due to their activation of EGFR transactivation. The next steps to take
are 1) to determine if these findings are due to the beta-blockers own ligand bias toward
beta-adrenergic 2 receptors or because system bias (due to the cell line having other
receptors that the beta-blockers can bind to) and 2) to conduct a qualitative and
quantitative analysis of these beta-blockers' ability to engage one or more of the three
pathways (G protein switching to Gi/o,EGFR pathway activation, and the presence of
beta-arrestin) known to link beta-adrenergic receptors to ERK phosphorylation. Doing
this and organizing all of the information in a table like the one above, would provide
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researchers a clear understanding of beta-blockers mechanism of action and a more clear
idea of which drug will possibly be more successful in treating a patient's disease.
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